| Excerpt | Reference |
|---|
| "Two patients were treated for chronic hepatitis B with lamivudine and subsequently underwent renal transplantation." | ( Han, DJ; Jung, YO; Lee, YS; Park, JS; Park, SK; Yang, WS, 1998) |
| "Medical therapy of chronic hepatitis B aims at halting progression towards cirrhosis/hepatocellular carcinoma by inhibiting replication of hepatitis B virus in a sustained fashion (viral elimination)." | ( Lavanchy, D; Renner, EL, 1998) |
| "Prolonged therapy for chronic hepatitis B (HBV) with nucleoside analogs may result in the emergence of HBV mutants resistant to antivirals." | ( Pichoud, C; Seignères, B; Trépo, C; Wang, Z; Zoulim, F, 1999) |
| "A consensus meeting on the treatment of chronic hepatitis B infection was conducted in Hong Kong, in August 1997." | ( Carman, WF; Lam, SK; Lau, GK; Locarnini, SA; Lu, ZM; Okuda, K; Williams, R, 1999) |
| "Sixteen patients with chronic hepatitis B, 4 patients with decompensated hepatic cirrhosis and 4 patients having undergone LTx with recurrence of HVB infection were treated with the oral administration of 100 mg/day of lamivudine for one year." | ( Buti, M; Cotrina, M; Cruz de Castro, E; Esteban, R; Guardia, J; Jardí, R; Rodríguez, F, 1999) |
| "In a recent phase II clinical study, 13 chronic hepatitis B-infected patients treated daily with 30 mg adefovir dipivoxil for 12 weeks displayed a median 4." | ( Gibbs, CS; Rooney, JF; Toole, JJ; Tsiang, M, 1999) |
| "A 21 year-old male patient with chronic hepatitis B was treated with lamivudine 150 mg daily after withdrawal of a short course of oral prednisolone (30 mg daily for 3 weeks, 15 mg daily for 1 week)." | ( Chien, RN; Liaw, YF, 1999) |
| "In patients with chronic hepatitis B, brief lamivudine therapy suppresses hepatitis B virus (HBV) DNA but results infrequently in sustained losses of virus replication posttreatment." | ( Brown, N; Casey, DE; Condreay, L; Crowther, L; Dienstag, JL; Gelb, LD; Gitlin, N; Lissoos, T; Mitchell, M; Rubin, M; Schiff, ER, 1999) |
| "patients with previously untreated chronic hepatitis B, one year of lamivudine therapy had favorable effects on histologic, virologic, and biochemical features of the disease and was well tolerated." | ( Brown, NA; Condreay, LD; Crowther, L; Dienstag, JL; Goodman, Z; Hann, HW; Perrillo, RP; Rubin, M; Schiff, ER; Woessner, M; Wright, TL, 1999) |
| "We have treated 35 patients with chronic hepatitis B and decompensated cirrhosis with lamivudine 100 mg or 150 mg orally once daily." | ( Bilodeau, M; Condreay, LD; Fenyves, D; Heathcote, EJ; Leduc, R; Margulies, M; Peltekian, K; Pomier-Layrargues, G; Villeneuve, JP; Willems, B; Wong, F, 2000) |
| "Twenty-four patients with chronic hepatitis B virus (HBV), antibody to hepatitis B e antigen (anti-HBe), HBV DNA positivity, and alanine transaminase (ALT) elevation who failed previous interferon alfa (IFN-alpha) therapy were included in a pilot study of combination therapy with ribavirin and IFN-alpha." | ( Carreño, V; Clouet, R; Cotonat, T; López-Alcorocho, JM; Manzarbeitia, F; Pardo, M; Quiroga, JA, 2000) |
| "Fifty-three patients with chronic hepatitis B and active viral replication were studied for 4 weeks while on treatment and for 12 weeks after treatment with the oral nucleoside analogue lamivudine." | ( Barber, J; Boxall, E; Dallow, N; Johnson, M; Kelly, D; McPhillips, P; Mieli-Vergani, G; Roberts, EA; Sokal, EM, 2000) |
| "In IFN-naive patients with chronic hepatitis B (and compensated liver disease) alpha-interferon is still the first-line therapy." | ( Erhardt, A; Häussinger, D; Heintges, T; Petry, W, 2000) |
| "Forty-four chronic hepatitis B virus (HBV) carriers, who were anti-HBe- and HBV-DNA-positive, were randomized, with stratification for the presence of cirrhosis at baseline liver biopsy, to receive either thymosin-alpha1 at a dose of 900 microg/m2 twice a week for six months or no treatment." | ( Airoldi, A; Bettale, G; Franzone, JS; Ideo, G; Severini, R; Tempini, S; Tinelli, C; Zavaglia, C, 2000) |
| "The treatment of HBeAg-negative chronic hepatitis B with alpha interferon alone is unsatisfactory." | ( Alexopoulou, A; Hadziyannis, S; Manesis, E; Papakonstantinou, A; Petraki, K, 2000) |
| "Five patients with chronic hepatitis B virus (HBV) infection developed resistance to lamivudine after 9 to 19 months of treatment." | ( Gutfreund, K; Hirsch, K; Lamy, P; Murray, A; Perrillo, R; Schiff, E; Statler, A; Wright, T; Yoshida, E, 2000) |
| "Thirteen consecutive patients with chronic hepatitis B infection, Child's-Pugh-Turcotte (CPT) score of > or =10 (median score=11) and detectable circulating hepatitis B DNA (range 15 to 9634 pg/ml) were included and treated with lamivudine 150 mg once daily." | ( Bass, NM; Yao, FY, 2000) |
| "Acute exacerbations of chronic hepatitis B virus (HBV) infection occur after withdrawal of lamivudine therapy in approximately 16% of patients and are considered of little clinical significance." | ( de Man, RA; Honkoop, P; Niesters, HG; Schalm, SW; Zondervan, PE, 2000) |
| "Standard treatment of chronic hepatitis B virus infection includes the use of interferon-a and antiviral nucleoside analogues, alternatively." | ( Gerken, G, 2000) |
| "Treatment of chronic hepatitis B is directed at interrupting the natural history and clinical outcomes of the disease." | ( Farrell, GC, 2000) |
| "INTERFERON ALPHA AND LAMIVUDINE: Chronic hepatitis B is currently treated with interferon alpha and lamivudine." | ( Buffet, C; Perlemuter, G, 2001) |
| "A 61-year-old man with chronic hepatitis B was treated with interferon (IFN)-alpha for flare-up after the emergence of a lamivudine-induced YMDD motif mutant." | ( Arase, Y; Chayama, K; Ikeda, K; Kobayashi, M; Kumada, H; Murashima, N; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A, 2001) |
| "A study in Chinese patients with chronic hepatitis B showed that treatment with lamivudine for 1 year significantly improves liver histology and enhances hepatitis B e antigen (HBeAg) seroconversion compared with placebo." | ( Chang, TT; Chien, RN; Condreay, LD; Dent, JC; Edmundson, S; Guan, R; Lai, CL; Lee, CM; Leung, NW; Lim, SG; Ng, KY; Wu, PC, 2001) |
| "The 80 chronic hepatitis B patients were divided into two groups, the control group was treated with routine liver protective and jaundice regressing drugs while the treated group was additionally administered with Tiopromin besides the routine treatment." | ( Chen, C; Qiu, S; Tan, Z, 2000) |
| "Thirty-six patients with chronic hepatitis B were treated with interferon alpha." | ( Deng, H; Deng, L; Deng, Y; Peng, X; Yao, J; Zhou, Y, 2001) |
| "In patients treated for chronic hepatitis B infection the cumulative incidence of viral resistance reaches over 50% after 3 years." | ( Fischer, KP; Gutfreund, KS; Tyrrell, DL, 2001) |
| "In the interferon (IFN) treatment of chronic hepatitis B, there is no accepted definition of virological response as measured by highly sensitive HBV DNA assays." | ( Hannoun, C; Horal, P; Krogsgaard, K; Lindh, M, 2001) |
| "For the treatment of chronic hepatitis B (CHB) two drugs have been licensed world-wide: interferon-alpha (IFN) and lamivudine." | ( de Man, RA; Janssen, HL; Niesters, HG; Schalm, SW; van Nunen, AB; Wolters, LM, 2001) |
| "Trials of thymosin treatment in chronic hepatitis B virus infection have been small and the results have been inconsistent." | ( Chan, HL; Sung, JJ; Tam, W; Tang, JL, 2001) |
| "placebo (or usual care) in the treatment of chronic hepatitis B virus infection were identified through MEDLINE, EMBASE and the Cochrane Register of Clinical Trials." | ( Chan, HL; Sung, JJ; Tam, W; Tang, JL, 2001) |
| "Reactivation of chronic hepatitis B virus (HBV) infection is a major complication when HBV carriers receive immunosuppressive therapy." | ( Chizuka, A; Hori, A; Kanda, Y; Kobayashi, Y; Makimoto, A; Mineishi, S; Nakai, K; Niiya, H; Ohnishi, M; Saito, T; Takaue, Y; Takeuchi, T; Tanosaki, R; Tobinai, K; Watanabe, T; Won Kim, S, 2002) |
| "As to anti-viral treatment of chronic hepatitis B, the triplex superimposed treatment had better efficacy than lamivudine alone." | ( Du, KF; Liu, H; Lu, ZG; Wu, L; Xue, P, 2001) |
| "Treatment of chronic hepatitis B is directed at interrupting the natural history by suppressing HBV replication before development of any significant irreversible liver cell damage." | ( Pramoolsinsup, C, 2002) |
| "HBV DNA positive chronic hepatitis B patients were treated with lamivudine 150-600 mg daily for four weeks." | ( de Man, RA; Hansen, BE; Niesters, HG; Schalm, SW; Wolters, LM; Zeuzem, S, 2002) |
| "Lamivudine therapy is effective for chronic hepatitis B infection in adults." | ( Areias, JA; Badia, IB; Bell, MS; Gardner, SD; Greensmith, MJ; Jonas, MM; Kelley, DA; Little, NR; Mizerski, J; Schwarz, KB; Sokal, EM, 2002) |
| "In children with chronic hepatitis B, 52 weeks of treatment with lamivudine was associated with a significantly higher rate of virologic response than was placebo." | ( Areias, JA; Badia, IB; Bell, MS; Gardner, SD; Greensmith, MJ; Jonas, MM; Kelley, DA; Little, NR; Mizerski, J; Schwarz, KB; Sokal, EM, 2002) |
| "Fifty patients with anti-HBe-positive chronic hepatitis B were treated for 12 months with LAM at 100mg/day (26 pts) or with IFN at 5MU t." | ( Andriulli, A; Facciorusso, D; Gravinese, E; Guastadisegni, A; Insalata, M; Leandro, G; Niro, GA; Pastore, G; Santantonio, T; Sinisi, E, 2002) |
| "In anti-HBe-positive chronic hepatitis B, a 12-month course of LAM/IFN combination therapy is as beneficial as LAM monotherapy, however, the combination regimen appeared to prevent or delay the emergence of YMDD variants." | ( Andriulli, A; Facciorusso, D; Gravinese, E; Guastadisegni, A; Insalata, M; Leandro, G; Niro, GA; Pastore, G; Santantonio, T; Sinisi, E, 2002) |
| "A total of 805 adults with chronic hepatitis B were treated either with lamivudine (n = 406), matching placebo (n = 196), interferon (n = 68), or the combination of lamivudine plus interferon (n = 135)." | ( Atkins, M; Brown, NA; Dienstag, JL; Gardner, SD; Heathcote, EJ; Lai, CL; Liaw, YF; Perrillo, RP; Schalm, SW; Schiff, ER; Woessner, M, 2002) |
| "Twenty-four patients with chronic hepatitis B who were non-responders to previous IFN therapy were randomized to receive an IFN and GMCSF (group A, n = 10) or IFN and lamivudine (group B, n = 14) combination for 6 months." | ( Guptan, RC; Kazim, SN; Sarin, SK; Thakur, V, 2002) |
| "A total of 119 patients with chronic hepatitis B were randomly divided into treatment group (n = 65, aged 24 +/- 12) and control group (n = 54, aged 25 +/- 11)." | ( Cui, S; Fan, G; Wang, M, 2002) |
| "Liver fibrosis in chronic hepatitis B with slight liver injury was more suitable to SA-B in anti-fibrotic treatment." | ( Gu, HT; Hu, YY; Liu, C; Liu, CH; Liu, P; Xu, LM; Xu, ZQ; Xue, HM; Zhang, ZQ; Zhu, DY, 2002) |
| "Among 53 chronic hepatitis B patients who had acute exacerbation and had finished lamivudine therapy after at least 6 months of treatment, 31 patients achieved full HBeAg seroconversion twice at least 1 month apart, and subsequently stopped lamivudine therapy." | ( Changchien, CS; Chen, TM; Lee, CM; Liao, CA; Lu, SN; Ong, GY; Tung, HD; Wang, JH, 2002) |
| "Treatment of chronic hepatitis B is aimed at sustained suppression of HBV replication and remission of liver disease." | ( Lok, AS; Wai, CT, 2002) |
| "As a result, a large proportion of chronic hepatitis B patients continue to be in need of a safe and efficacious therapy." | ( Marcellin, P, 2002) |
| "Currently available treatments for chronic hepatitis B (interferon [IFN]-alpha and lamivudine [3TC]) have limited long-term utility because of side effects or of the development of resistance." | ( Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P, 2002) |
| "Combination treatment of chronic hepatitis B with prednisone, IFN-alpha, and FAM seems to be a safe and effective treatment option for children surviving pediatric malignancy." | ( Benesch, M; Deutsch, J; Dornbusch, HJ; Kerbl, R; Kessler, HH; Lackner, H; Moser, A; Schwinger, W; Sovinz, P; Urban, C, 2002) |
| "The main objective of chronic hepatitis B treatment is to obtain the complete inhibition of the HBV virus by Hbe-antigen antibody seroconversion which would therefore significantly increase patient survival." | ( Benhamou, Y; Cacoub, P, 2002) |
| "We aimed to treat patients with chronic hepatitis B on long-term treatment with lamivudine who developed lamivudine-resistant hepatitis B virus (HBV) mutants along with clinical relapses." | ( Akuta, N; Arase, Y; Ikeda, K; Kobayashi, M; Kumada, H; Miyakawa, Y; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A, 2002) |
| "Of 217 patients with chronic hepatitis B who had been treated with lamivudine for 1-6 years, 23 (11%) developed lamivudine-resistant hepatitis B virus (HBV) mutants." | ( Akuta, N; Arase, Y; Ikeda, K; Kobayashi, M; Kumada, H; Miyakawa, Y; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A, 2002) |
| "A total of 74 patients with chronic hepatitis B who showed viral breakthrough after at least 6 months of lamivudine treatment were included in this study." | ( Ahn, SH; Baek, SJ; Bak, JJ; Bak, YT; Byun, KS; Chang, YJ; Choi, CW; Choi, DW; Jeong, WS; Jo, NY; Kim, JS; Kim, KO; Lee, CH; Lee, MS; Oh, SN; Yeon, JE; Yim, HJ, 2002) |
| "Lamivudine therapy in chronic hepatitis B has been shown to be effective in inhibiting HBV replication." | ( Choi, DJ; Chung, MG; Hwang, YJ; Ju, KT; Kim, JH; Kim, SS; Kim, YK; Koo, YS; Kwon, OS; Park, DK, 2002) |
| "A rational treatment strategy for chronic hepatitis B virus (HBV) infection might involve the modulation of immunity after the reduction of viremia and antigenemia." | ( Cote, PJ; Gerin, JL; Korba, BE; Menne, S; Roneker, CA; Tennant, BC, 2002) |
| "Forty-four patients of chronic hepatitis B were divided into two groups, the treated group was treated with oxymatrine 0." | ( Chen, YX; Jiang, JH; Mao, BY, 2002) |
| "Oxymatrine is effective in treating chronic hepatitis B." | ( Chen, YX; Jiang, JH; Mao, BY, 2002) |
| "Lamivudine treatment in chronic hepatitis B leads to the reconstitution of virus-specific T cells in the circulation, but it is not clear whether this is the preferential result of T cell efflux from the liver or lymph nodes." | ( Behboudi, S; Bertoletti, A; Burroughs, AK; Dusheiko, GM; Gotto, J; Malacarne, F; Reignat, S; Webster, GJ; Williams, R, 2003) |
| "In patients with HBeAg-negative chronic hepatitis B, 48 weeks of adefovir dipivoxil treatment resulted in significant histologic, virologic, and biochemical improvement, with an adverse-event profile similar to that of placebo." | ( Brosgart, CL; Chang, TT; Fry, J; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Marcellin, P; Rizzetto, M; Tassopoulos, NC; Wulfsohn, MS; Xiong, S, 2003) |
| "Children with chronic hepatitis B infection treated with lamivudine after failure of interferon therapy had decreased HBV replication and improved ALT values." | ( Berkowitz, D; Daudi, N; Eshach-Adiv, O; Hartman, C; Hino, B; Kra-Oz, T; Rimon, N; Satinger, I; Shamir, R; Shouval, D, 2003) |
| "Forty subjects with chronic hepatitis B and hepatitis B e antigen (HBeAg) seroconversion following lamivudine therapy in previous trials were monitored after treatment to assess the durability of serologic responses." | ( Cianciara, J; Dienstag, JL; Gardner, S; Karayalcin, S; Kowdley, KV; Plisek, S; Schiff, E; Willems, B; Woessner, M, 2003) |
| "Treatment of chronic hepatitis B and C viruses (HBV and HCV) is still disappointing, and both are the major causes of liver cirrhosis and hepatocarcinoma." | ( Colella, F; Garaci, E; Pierimarchi, P; Rasi, G; Sinibaldi Vallebona, P, 2003) |
| "Current therapies for the treatment of chronic hepatitis B virus (HBV) infection do not eliminate viral replication once therapy is stopped, resulting in a rapid rebound of viremia in a majority of patients." | ( Barcena Marugan, R; Cid Gomez, L; Lopez Serrano, P, 2003) |
| "Lamivudine therapy in patients with chronic hepatitis B can induce the recovery of antiviral T cell responses." | ( Bertoletti, A; Boni, C; Cavalli, A; Cerioni, S; Ferrari, C; Jenkins, J; Lamonaca, V; Missale, G; Panebianco, R; Penna, A; Pilli, M; Rapti, I; Urbani, S, 2003) |
| "In the treatment of chronic hepatitis B (CHB) with lamivudine, adequate duration of the therapy remains to be determined." | ( Choi, MH; Chung, YH; Jang, MK; Kim, JA; Lee, HC; Lee, YS; Park, NH; Ryu, SH; Shin, JW; Suh, DJ, 2003) |
| "It is indicated for the treatment of chronic hepatitis B in adults." | ( Dando, T; Plosker, G, 2003) |
| "During treatment of chronic hepatitis B with lamivudine, changes in the level of hepatitis B virus (HBV) DNA were investigated using a real-time polymerase chain reaction (PCR) method with a detection limit of 1." | ( Hino, T; Hisamochi, A; Ide, T; Koga, Y; Kumashiro, R; Kuwahara, R; Murashima, S; Ogata, K; Sata, M; Tanaka, E; Tanaka, K, 2003) |
| "Therapy of chronic hepatitis B virus (HBV) infection with the polymerase inhibitor lamivudine frequently is associated with the emergence of viral resistance." | ( Arnold, E; Das, K; Delaney, WE; Gibbs, CS; Miller, MD; Westland, CE; Xiong, S; Yang, H, 2003) |
| "Forty-five patients with chronic hepatitis B virus (HBV) infection who were treated with lamivudine for more than 1 year were enrolled." | ( Hino, T; Hisamochi, A; Ide, T; Koga, Y; Kumashiro, R; Kuwahara, R; Murashima, S; Ogata, K; Sata, M; Tanaka, E; Tanaka, K, 2004) |
| "In therapy of chronic hepatitis B, there are new and exciting developments in antivirals such as nucleotide analogues." | ( Cho, YK; Kim, BI, 2003) |
| "124 patients with chronic hepatitis B infection, who represented viral breakthrough during lamivudine therapy, were included." | ( Bang, SJ; Joo, KR; Kim, DH; Park, JH; Park, NH; Shin, JW, 2003) |
| "To summarize, the future of chronic hepatitis B therapy seems to be the combination of different drugs." | ( Buti, M; Esteban, R, 2003) |
| "Lamivudine is used for the treatment of chronic hepatitis B (CH-B), and exhibits excellent antiviral activity." | ( Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Matsuda, M; Saitoh, S; Satoh, J; Someya, T; Suzuki, F; Suzuki, Y; Takagi, K; Tsubota, A, 2004) |
| "The efficacy of lamivudine therapy in chronic hepatitis B is well established." | ( Chan, HL; Leung, NW; Tam, JS; Wong, ML; Wong, VW, 2004) |
| "Treatment for chronic hepatitis B with lamivudine is often hampered by the emergence of point mutations in the YMDD motif of the HBV DNA polymerase gene that confer drug resistance." | ( Echevarría, JM; León, P; Pozo, F, 2004) |
| "We present a male patient with chronic hepatitis B and fasciolosis who responded to chronic hepatitis treatment with hepatitis B virus (HBV) vaccine, interferon-alpha-2b and lamivudine." | ( Cicioglu Aridogan, B; Demirci, M; Isler, M; Korkmaz, M; Senol, A, 2004) |
| "Sixty-three children with chronic hepatitis B infection were treated randomly with thrice-weekly subcutaneous injections of 5 MU/m2 recombinant IFN-alpha2a (n=29) or recombinant IFN-alpha2b (n=34) with the same dose, intervals for 6 months." | ( Akman, S; Aydogdu, S; Dikici, B; Doganci, T; Ozgenc, F; Targan, S; Yagci, RV, 2004) |
| "Treatment of chronic hepatitis B patients resistant to lamivudin remains to be established." | ( Akarca, US; Batur, Y; Ersöz, G; Günşar, F; Karasu, Z, 2003) |
| "Patients with chronic hepatitis B infection and detectable HBV DNA received lamivudine and famciclovir combination therapy." | ( Alsatie, M; Chalasani, N; Eckert, G; Kwo, PY; Lumeng, L; Shen, H, 2004) |
| "The treatment plan for chronic hepatitis B needs to be individualized based on the stage of both viral infections and the available options." | ( Thio, CL, 2004) |
| "HJD is effective for treating chronic hepatitis B, and its effect seems to relate with the improvement of the TCRVbeta7 expression of chronic hepatitis B patients, thus activating T cells and eliminating HBV." | ( Chen, ZX; Huang, BJ; Lao, SX; Zhang, SJ, 2004) |
| "In hepatitis B e antigen-negative chronic hepatitis B patients under long term lamivudine monotherapy, serum b2m levels at three months of treatment, compared with baseline levels, are good predictors of risk for virological breakthrough." | ( Elefsiniotis, IS; Glynou, I; Kada, H; Mavrogiannis, C; Pantazis, KD; Scarmeas, N, 2004) |
| "Currently approved treatments for chronic hepatitis B are limited by low rates of sustained response, side effects, or drug resistance." | ( Lok, AS, 2004) |
| "70 patients of chronic hepatitis B were administered 100 mg Lamivudine orally daily for 1 year." | ( Guan, XQ; Xiao, YH; Yang, C; Yuan, Z, 2004) |
| "120 patients with chronic hepatitis B were treated with lamivudine (100 mg/d) over 24 weeks." | ( Deng, H; Fu, J; Lv, Y, 2004) |
| "YMDD mutants were detected in 51 chronic hepatitis B patients who experienced a flare-up of alanine aminotransferase (ALT) during lamivudine treatment." | ( Changchien, CS; Chen, CH; Chen, WJ; Hung, CH; Lee, CM; Lu, SN; Tung, HD; Wang, JH, 2004) |
| "Using this method, thirty patients with chronic hepatitis B and treated with lamivudine for at least one year were analysed for the lamivudine related mutations in polymerase gene." | ( Ding, JJ; Zhang, LS; Zhang, WS, 2004) |
| "Seventy-four patients with chronic hepatitis B were divided into 3 groups: 30 cases were enrolled in the sequential antiviral group in which patients received eight-week treatment with thymosin alpha1 (1." | ( Fan, HM; Lei, CL; Peng, XM; Tang, XP; Yang, Z; Yuan, XZ, 2004) |
| "Oral therapy for chronic hepatitis B remains suboptimal." | ( Corey, L; Engelberg, R; Ferrenberg, J; Holte, S; Huang, ML; Sacks, SL; Shuhart, M; Wang, CC, 2004) |
| "Patients with HBeAg-negative chronic hepatitis B had significantly higher rates of response, sustained for 24 weeks after the cessation of therapy, with peginterferon alfa-2a than with lamivudine." | ( Bonino, F; Button, P; Diago, M; Farci, P; Germanidis, G; Gurel, S; Hadziyannis, S; Jin, R; Lai, MY; Lau, GK; Lu, ZM; Marcellin, P; Piratvisuth, T; Pluck, N; Yurdaydin, C, 2004) |
| "The treatment of the patient with chronic hepatitis B virus infection (HBV) must be carried out with the knowledge that the percentage of patients infected with the B virus that develop chronic hepatitis remains between 5-10%." | ( Carreño, N; Moreno, D; Sangro, B, 2004) |
| "Treatment of chronic hepatitis B needs to consider two aspects." | ( de Gottardi, A; Negro, F, 2004) |
| "For HBeAG-positive chronic hepatitis B and HBeAG-negative chronic hepatitis B, the duration of interferon therapy is 4-6 months and 12 months, respectively." | ( Fung, SK; Lok, AS, 2004) |
| "In hepatitis B e antigen-negative chronic hepatitis B, adefovir dipivoxil was recently found to maintain its efficacy even after 3 years of therapy." | ( Hadziyannis, SJ; Papatheodoridis, GV, 2004) |
| "Although the management of chronic hepatitis B has improved over the last decade, none of the available therapeutic agents, IFN-alpha, lamivudine and adefovir dipivoxil, can achieve sustained off-therapy responses in most cases." | ( Hadziyannis, SJ; Papatheodoridis, GV, 2004) |
| "Diagnosis and treatment of chronic hepatitis B serves prevention of liver cirrhosis and hepatocellular carcinoma as well as elimination of the sources of further infections." | ( Telegdy, L, 2004) |
| "Treatment of chronic hepatitis B is aimed at sustained suppression of HBV replication and remission of liver disease." | ( Bahar, A; Karademir, F, 2004) |
| "The primary aim in the treatment of chronic hepatitis B is to induce sustained disease remission and prevent serious complications like liver failure and/or hepatocellular carcinoma." | ( Janssen, HL; Sprengers, D, 2005) |
| "We describe the case of a patient with chronic hepatitis B who became resistant to lamivudine and was treated successfully with adefovir dipivoxil in addition to lamivudine." | ( Chevallier, M; Chevallier, P; Durantel, S; Lot, M; Maynard, M; Parvaz, P; Trepo, C; Zoulim, F, 2005) |
| "In patients with HBeAg-positive chronic hepatitis B, staggered combination treatment with pegylated interferon-alpha2b and lamivudine may lead to a higher rate of virologic response than lamivudine monotherapy." | ( Chan, FK; Chan, HL; Chim, AM; Hui, AY; Hung, LC; Lam, CW; Lee, YT; Leung, NW; Liew, CT; Sung, JJ; Tam, JS; Wong, VW, 2005) |
| "Treatment of chronic hepatitis B has been greatly improved by the use of lamivudine, but mutations occur in the polymerase region of hepatitis B virus (HBV) and lamivudine-resistant mutants frequently develop." | ( Asaka, M; Chuma, M; Hige, S; Nakanishi, M; Natsuizaka, M; Ogawa, K; Ono, Y; Yoshida, S, 2005) |
| "Treatment options for chronic hepatitis B virus (HBV) infection have disparate risks and benefits." | ( Dulai, GS; Farid, M; Gralnek, IM; Kanwal, F; Martin, P; Spiegel, BM, 2005) |
| "Lamivudine therapy for chronic hepatitis B has been associated with changes in different regions of the hepatitis B virus nucleotide sequence." | ( Buti, M; Esteban, R; Guardia, J; Jardi, R; Rodriguez-Frias, F; Schaper, M; Valdes, A, 2005) |
| "A new nucleoside analog for treating chronic hepatitis B infection." | ( , 2005) |
| "Totally 595 patients with chronic hepatitis B were treated with lamivudine 100 mg/day for 12 months." | ( Dong, QM; He, ZP; Song, C; Song, SJ; Wei, HS; Xiao, YP; Yan, J; Zhuang, H, 2005) |
| "Hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients receiving either lamivudine monotherapy or combination of peginterferon and lamivudine had liver biopsy at the end of 1 year therapy and were followed for 52 more weeks after cessation of therapy." | ( Bowden, S; Chan, HL; Hui, AY; Leung, NW; Liew, CT; Locarnini, S; Sung, JJ; Wong, ML; Wong, VW, 2005) |
| "In conclusion, in HBeAg-negative chronic hepatitis B, long-term nucleos(t)ide analog therapy starting with lamivudine significantly improves survival and reduces the risk of major complications, compared with interferon non-sustained responders or untreated patients." | ( Dimakopoulos, K; Dimou, E; Hadziyannis, SJ; Kitis, G; Manesis, E; Manolakopoulos, S; Papatheodoridis, GV; Rapti, I; Tzourmakliotis, D, 2005) |
| "Lamivudine treatment in patients with chronic hepatitis B virus (HBV) infection may improve clinical state and suppress viral replication before liver transplantation." | ( Chan, SC; Fan, ST; Lau, GK; Liu, CL; Lo, CM; Ng, IO, 2005) |
| "In patients with HBeAg-negative chronic hepatitis B, the benefits achieved from 48 weeks of adefovir dipivoxil were lost when treatment was discontinued." | ( Arterburn, S; Brosgart, CL; Chang, TT; Currie, G; Goodman, Z; Hadziyannis, SJ; Heathcote, EJ; Kitis, G; Lim, SG; Ma, J; Marcellin, P; Rizzetto, M; Tassopoulos, NC; Xiong, S, 2005) |
| "The use of Lamivudine in chronic hepatitis B (CHB) is well known, however the reported rate of HBeAg sero-conversion and its durability post-treatment have varied considerably." | ( Alexander, G; Baba, CS; Chetri, K; Choudhuri, G; Negi, TS, 2005) |
| "In Korean chronic hepatitis B patients, the relapse rate is high after termination of lamivudine therapy for patients with HBeAg loss." | ( Bak, YT; Byun, KS; Chang, YJ; Kim, JH; Kim, JS; Kim, JY; Kwon, OS; Lee, CH; Park, JJ; Yeon, JE; Yim, HJ, 2005) |
| "To prevent relapse in patients with chronic hepatitis B infection after lamivudine therapy, age and serum bilirubin level of patients as well as a prolonged duration of additional lamivudine therapy should be considered." | ( Bak, YT; Byun, KS; Chang, YJ; Kim, JH; Kim, JS; Kim, JY; Kwon, OS; Lee, CH; Park, JJ; Yeon, JE; Yim, HJ, 2005) |
| "To study the clinical features of chronic hepatitis B (CHB) patients with tyrosine-methionine-aspartate-aspartate (YMDD) mutation after lamivudine therapy." | ( Hou, W; Liu, KZ; Ni, Q; Zumbika, E, 2005) |
| "Recent guidelines for the treatment of chronic hepatitis B based on the accumulated knowledge on the disesase pathogenesis and treatment outcome are presented." | ( Morović, M, 2005) |
| "The goal of treating children with chronic hepatitis B is the prevention of complications rather than the urgency of stopping the disease." | ( Kekez, AJ, 2005) |
| "Treatment of chronic hepatitis B virus (HBV) infection with lamivudine is effective and well-tolerated." | ( Guan, S; Huang, YX; Lu, M; Roggendorf, M; Wang, XY; Xu, Y; Yin, YK; Zhang, JM, 2006) |
| "HJT is effective in treating chronic hepatitis B." | ( Chen, ZX; Gu, YL; Guan, SH; Hu, HT; Lao, SX; Zhang, CY; Zhang, SJ, 2005) |
| "We present a case of chronic hepatitis B with membranous nephropathy, that was improved by lamivudine treatment." | ( Ikeda, H; Itoh, F; Kimura, K; Koike, J; Kondo, S; Okuse, C; Suzuki, M; Takahashi, H; Yamada, N; Yotsuyanagi, H, 2006) |
| "In patients with HBeAg-negative chronic hepatitis B, long-term therapy is usually required, as off-treatment relapse is common." | ( Jacobson, IM, 2006) |
| "Treatment of chronic hepatitis B (CHB) involves a number of complex and controversial issues." | ( Alberti, A; Buti, M; Cooksley, WG; Fried, MW; Gish, RG; Hadziyannis, SJ; Keeffe, EB; Liaw, YF; Naoumov, NV; Perrillo, RP; Peters, M; Schalm, S; Schiff, ER; Thio, CL; Tsai, N, 2006) |
| "One patient with chronic hepatitis B virus (HBV) infection developed resistance to lamivudine after 15 months of treatment." | ( Lai, V; Mirza, D; Mutimer, D; Zhang, WX, 2006) |
| "Among patients with HBeAg-negative chronic hepatitis B who had not previously been treated with a nucleoside analogue, the rates of histologic improvement, virologic response, and normalization of alanine aminotransferase levels were significantly higher at 48 weeks with entecavir than with lamivudine." | ( Chang, TT; Cheinquer, H; Colonno, R; Cross, A; DeHertogh, D; Fernandes, L; Goodman, Z; Lai, CL; Lok, AS; Shouval, D; Wilber, R; Zink, RC, 2006) |
| "A total of 93 naive children (43 chronic hepatitis B carriers, 50 chronic hepatitis B patients) were treated in three groups with HBsAg vaccine, levamisole or levamisole plus HBsAg vaccine." | ( Bayraktaroğlu, Z; Coşkun, Y; Demirci, F; Karaoğlan, I; Karaoğlan, M; Okan, V, 2005) |
| "In HBeAg-negative chronic hepatitis B, initial response to lamivudine therapy is associated with necroinflammation, while baseline serum hepatitis B virus DNA exceeding 10(6) copies/mL is a strong predictor for breakthrough because of drug-resistant mutations." | ( Avgerinos, A; Bethanis, S; Economou, M; Elefsiniotis, J; Karatapanis, S; Manolakopoulos, S; Sourvinos, G; Spandidos, D; Touloumi, G; Triantos, C; Tzourmakliotis, D; Vlachogiannakos, J, 2006) |
| "Current treatments for chronic hepatitis B virus (HBV) infection include the use of interferon-alpha and of nucleoside analogs lamivudine, adefovir and entecavir." | ( Ang, TH; Bai, J; Chen, Y; Kong, KH; Lam, Y; Li, Y; Lim, SG; Tan, TM, 2006) |
| "Sixteen chronic hepatitis B patients treated with lamivudine were included and followed up for 48 weeks in this study." | ( Duan, XZ; Jin, B; Li, HW; Wang, FS; Wang, HF, 2006) |
| "Fifty-five chronic hepatitis B patients treated with lamivudine were included." | ( Itoh, Y; Kirishima, T; Kunimoto, K; Makiyama, A; Minami, M; Mori, K; Nakajima, T; Nakayama, M; Okanoue, T; Okita, M; Yamaoka, J; Yasui, K, 2006) |
| "In the linked cases of chronic hepatitis B, the choice of antiviral medicine in some patients could also be made on the basis of its efficacy in the persons previously treated with it, even without determining virus genotype." | ( Nozić, D, 2006) |
| "Registered treatment for chronic hepatitis B currently consists of (pegylated) interferon, lamivudine and adefovir, while entecavir is expected to be licensed in the short term." | ( Buster, EH; Janssen, HL, 2006) |
| "Lamivudine is an effective therapy in chronic hepatitis B patients, but the emergence of resistant hepatitis B virus (HBV) mutants is a major concern." | ( Cho, M; Heo, J; Kang, DH; Kim, GH; Lee, DH; Park, HS; Song, GA, 2006) |
| "Some children with chronic hepatitis B are candidates for treatment." | ( Jonas, MM, 2006) |
| "Treatment of chronic hepatitis B (CHB) alone with interferon or lamivudine alone or in combination is effective in only a small proportion of patients." | ( Hissar, S; Kumar, M; Sarin, SK; Sharma, BC, 2006) |
| "The goal of anti-chronic hepatitis B therapy is to prevent the progression of liver disease to cirrhosis which may effect in development of liver failure or HCC." | ( Berak, H; Cybula, A; Horban, A; Stańczak, JJ; Wasilewski, M, 2006) |
| "Sequential treatment of chronic hepatitis B with lamivudine and interferon-alpha monotherapies is as effective as lamivudine-alone treatment in Chinese patients." | ( Han, B; Jin, LJ; Shi, M; Wang, RS; Xu, YP; Yang, ZJ; Zhang, H; Zhang, Y; Zhu, YF, 2006) |
| "At present sequential monotherapy for chronic hepatitis B with hepatitis B virus (HBV)-polymerase inhibitors is clinical practice." | ( Berg, T; Berger, F; Bruno, R; Carlebach, A; Hoffmann, C; Jaeger, H; Lutz, T; Mauss, S; Nelson, M; Rockstroh, J; Schmutz, G; Schürmann, D; Schwarze-Zander, C; Sheldon, J; Soriano, V; Stoehr, A; von Boemmel, F; Wolf, E, 2006) |
| "Long-term antiviral therapy of chronic hepatitis B can lead to regression of liver cirrhosis in patients after organ transplantation, unless viral resistance occurs." | ( Bara, C; Böker, KH; Deterding, K; Haverich, A; Manns, MP; Meyer, S; Pethig, K; Potthoff, A; Tillmann, HL; Wedemeyer, H, 2006) |
| "120 patients with mild or moderate Chronic Hepatitis B (CHB) were randomly divided into two groups: 80 patients in treatment group and 40 in control group." | ( Huang, XL; Shen, WS; Wang, FL; Wang, YZ; Xu, GL; Yang, HZ; Yang, YW, 2006) |
| "She was diagnosed as chronic hepatitis B infection a few years ago but did not receive any specific treatment." | ( Baik, du S; Kim, BH; Kim, HJ; Kim, SB; Seo, PJ; Shin, JE; Song, IH; Yun, SY, 2006) |
| "Seventy-nine chronic hepatitis B patients were randomly divided into the SMI group (n=47) and the SI group (n=32), they were treated with SMI and SI respectively on the basis of conventional treatment." | ( Jin, CX; Sun, HF; Yang, J, 2006) |
| "Success in antiviral therapy for chronic hepatitis B is supported by highly sensitive PCR-based assays for hepatitis B virus (HBV) DNA." | ( Allice, T; Cerutti, F; Colucci, G; Franchello, A; Gabella, S; Ghisetti, V; Marzano, A; Pittaluga, F; Varetto, S, 2007) |
| "Standard treatments for chronic hepatitis B (CHB) include interferon-alpha (IFN-alpha) and lamivudine (LAM), but these are associated with adverse effects and viral resistance, respectively." | ( Davidson, P; Jones, J; Price, A; Shepherd, J; Takeda, A, 2007) |
| "It is concluded that in HBeAg-negative chronic hepatitis B patients with ALT levels above 5x ULN, a 6-12 month course of lamivudine therapy may achieve sustained an off-treatment response in approximately one-third of patients." | ( Chien, RN; Liaw, YF, 2006) |
| "Treatment of chronic hepatitis B (CHB) with lamivudine (3TC) is limited by development of drug-resistant mutants at the YMDD motif." | ( Chan, HL; Chan, HY; Chow, KC; Ding, C; Hui, AY; Lo, YM; Sung, JJ; Wong, GL; Wong, VW, 2006) |
| "Most chronic hepatitis B patients do not undergo a curative response to interferon-alpha or nucleoside/nucleotide-based regimens and require long-term therapy." | ( Delaney, WE, 2007) |
| "The ultimate goals of chronic hepatitis B (CHB) therapy are decreases in the incidence of cirrhosis, end-stage liver disease and HCC." | ( Rivkin, A, 2007) |
| "A total of 220 patients with chronic hepatitis B treated with standard interferon alpha (112), pegylated interferon alpha-2a (23), or lamivudine (85) were investigated and assessed for the HBeAg seroconversion and/or undetectable HBV-DNA." | ( Pár, A; Szalay, F; Tornai, I, 2007) |
| "Treatment of chronic hepatitis B in renal transplant recipients remains one of the major problems in clinical nephrology." | ( Bakulin, I; Balakirev, E; Baranova, F; Chervinko, V; Kovalchuk, A; Novozhenov, V; Stahanova, V; Stanke, A; Stenina, I; Zolotarevsky, V; Zubkin, M, 2007) |
| "A small proportion of chronic hepatitis B patients have persistently detectable serum hepatitis B virus (HBV) DNA despite lamivudine therapy." | ( Bak, YT; Byun, KS; Kim, JH; Kim, JS; Lee, CH; Park, JJ; Seo, YS; Yeon, JE; Yim, HJ; Yu, SK, 2007) |
| "We enrolled 221 chronic hepatitis B patients who underwent lamivudine therapy for more than 6 months." | ( Bak, YT; Byun, KS; Kim, JH; Kim, JS; Lee, CH; Park, JJ; Seo, YS; Yeon, JE; Yim, HJ; Yu, SK, 2007) |
| "Treatment of chronic hepatitis B virus (HBV) infection could combine potent antiviral drugs and therapeutic vaccines to overcome immunological tolerance and induce the recovery phenotype to protect against disease progression." | ( Cote, PJ; Gerin, JL; Menne, S; Tennant, BC, 2007) |
| "Thirty-three patients with chronic hepatitis B refractory to lamivudine were enrolled to receive treatment with entecavir 1." | ( Jia, JD; Li, HY; Liang, L; Ma, H; Ren, JB; Sun, SJ; Wang, RL; Wang, Y, 2007) |
| "The outcomes of lamivudine-resistant chronic hepatitis B patients treated with long-term adefovir dipivoxil have not been well described." | ( Khoo, TL; Lee, AU; McCaughan, GW; Ngu, MC; Prakoso, E; Strasser, SI; van der Poorten, D, 2007) |
| "We analyzed 49 LAM-treated chronic hepatitis B patients infected with hepatitis B virus (HBV) genotype C." | ( Fukai, K; Imazeki, F; Kurihara, T; Mikata, R; Yokosuka, O; Zhang, KY, 2007) |
| "Thirty patients with chronic hepatitis B who had YMDD variants during lamivudine therapy and were followed up subsequently while receiving lamivudine alone for at least 6 months were examined retrospectively." | ( Enomoto, M; Habu, D; Kawada, N; Kohmoto, MT; Morikawa, H; Nishiguchi, S; Sakaguchi, H; Seki, S; Shiomi, S; Takeda, T; Tamori, A, 2007) |
| "Only in a minority of patients with chronic hepatitis B (CHB) will treatment with interferon (IFN)-alpha or nucleoside analogues lead to sustained virological response." | ( Binda, R; de Man, RA; Janssen, HL; Kusters, JG; Niesters, HG; Schalm, SW; Sprengers, D; van der Molen, RG, 2007) |
| "(1) For patients with HBeAg-positive chronic hepatitis B, peginterferon alfa-2a is the standard treatment used to prevent clinical complications and death." | ( , 2007) |
| "Lamivudine is used for the treatment of chronic hepatitis B patients." | ( Aghakhani, A; Banifazl, M; Gachkar, L; Keyvani, H; Ramezani, A; Roshan, MR; Velayati, AA, 2008) |
| "A total of 77 chronic hepatitis B patients who had not been treated with lamivudine were included in the study." | ( Aghakhani, A; Banifazl, M; Gachkar, L; Keyvani, H; Ramezani, A; Roshan, MR; Velayati, AA, 2008) |
| "Clinical data of 202 patients with chronic hepatitis B and 55 patients with post-hepatitis B cirrhosis treated with lamivudine therapy were analyzed and PCR as well as mispairing PCR-restricted fragment length polymorphism (RFLP) assay were applied." | ( Chen, JL; Fan, XL; Wang, L; Yan, J; Yu, H; Zhang, L, 2007) |
| "The treatment of chronic hepatitis B has improved dramatically over the last decade merits to the advent of nucleoside/nucleotide analogues and the use of pegylated interferons." | ( Amarapurkar, DN, 2007) |
| "In Chinese patients with chronic hepatitis B, telbivudine treatment for 52 weeks provided greater antiviral and clinical efficacy than lamivudine, with less resistance." | ( Brown, NA; Chao, G; Chen, C; Chen, Y; Constance, BF; Harb, G; He, Y; Hou, J; Jia, J; Niu, J; Ren, H; Tan, D; Wan, M; Wang, Q; Wang, Y; Wei, L; Wu, S; Xu, D; Xu, J; Yin, YK; Zhou, X; Zhu, L, 2008) |
| "Among patients with HBeAg-positive chronic hepatitis B, the rates of therapeutic and histologic response at 1 year were significantly higher in patients treated with telbivudine than in patients treated with lamivudine." | ( Brown, NA; Bzowej, N; Chao, G; Chen, Y; Constance, BF; Di Bisceglie, AM; Gane, E; Goodman, Z; Heathcote, EJ; Hsu, CW; Lai, CL; Liaw, YF; Moon, YM; Naoumov, NV; Rasenack, J; Thongsawat, S; Wang, Y; Zeuzem, S, 2007) |
| "In sub-Saharan Africa, children with chronic hepatitis B and who are treated with 3TC-based HAART are at risk of developing 3TC resistance." | ( Anaky, MF; Blanche, S; Chaix, ML; Fassinou, P; Inwoley, A; Kpozehouen, A; Msellati, P; Rouet, F; Rouzioux, C, 2008) |
| "We describe a patient with chronic hepatitis B viral infection and RA treated with etanercept." | ( Bond, MI; Carroll, MB, 2008) |
| "To date, 13 patients with chronic hepatitis B infection treated with TNF-alpha inhibitors have been reported: 11 with infliximab and 2 with etanercept." | ( Bond, MI; Carroll, MB, 2008) |
| "The ultimate goal of treatment for chronic hepatitis B (CHB) is to prevent hepatocellular carcinoma (HCC)." | ( Hann, HW, 2008) |
| "The impact of chronic hepatitis B virus (HBV) infection on viral suppression, immune recovery and mortality in HIV-1 infected patients on highly active antiretroviral treatment (HAART) is a matter of debate." | ( Christensen, PB; Engsig, F; Laursen, A; Møller, A; Nielsen, HI; Obel, N; Omland, LH; Skinhøj, P; Sørensen, HT; Weis, N, 2008) |
| "34 cases of chronic hepatitis B were treated by bicyclol tablets for 24 weeks." | ( Wang, RL; Ye, LK; Ye, XG, 2008) |
| "To assess quantitative serology in chronic hepatitis B virus (HBV) infection, testing by novel immunoassays has been carried out on 202 specimens from untreated patients and in 83 samples from 10 patients with chronic hepatitis B treated with lamivudine." | ( Badiale, R; Caltran, G; Galli, C; Gessoni, G; Orlandini, E; Penzo, L; Valverde, S, 2008) |
| "The long-term goals of therapy for chronic hepatitis B are to reduce serum HBV DNA to low or undetectable levels and ultimately reduce or prevent the development of cirrhosis and hepatocellular carcinoma." | ( Ayoub, WS; Keeffe, EB, 2008) |
| "To review the current treatment of chronic hepatitis B, with a focus on diagnosis and management of resistance and active management of suboptimal responses." | ( Ayoub, WS; Keeffe, EB, 2008) |
| "A total of 253 HBeAg-positive chronic hepatitis B patients who had a pretherapy serum ALT level over five times ULN and received lamivudine for 12-18 months were retrospectively collected." | ( Chen, DS; Chen, PJ; Kao, JH; Lai, MY; Liu, CJ; Tseng, TC; Wang, CC, 2008) |
| "We aim to evaluate in chronic hepatitis B virus-hepatitis C virus (HBV-HCV) coinfection the interplay of these viruses in liver tissue, peripheral blood mononuclear cells (PBMC), and plasma and to analyze the effect on disease course and response to treatment." | ( Coppola, N; Filippini, P; Imparato, M; Martini, S; Piai, G; Piccinino, F; Pisapia, R; Sagnelli, C; Sagnelli, E; Stanzione, M; Tonziello, G, 2008) |
| "Eighty-four patients with chronic hepatitis B who were refractory to lamivudine therapy were switched from lamivudine to daily oral doses of 0." | ( Imazeki, F; Kage, M; Katano, Y; Kumada, H; Moriyama, M; Omata, M; Sata, M; Seriu, T; Suzuki, F; Toyoda, J, 2008) |
| "HBV genotypes from 177 HBeAg-positive chronic hepatitis B (CHB) patients were identified and the patients were treated with ADV 10 mg per day for 48 weeks." | ( Deng, H; Guo, JJ; Hao, MJ; Huang, AL; Huang, WX; Li, QL; Peng, FY; Xin, XJ; Yang, C; Yuan, Z; Zeng, AZ; Zhang, ZZ, 2008) |
| "HBsAg loss is rare in chronic hepatitis B patients, even in the patients with long-term nucleos(t)ide analogue therapy; therefore information about serum HBsAg kinetics will be of value in understanding this unusual occurrence." | ( Chen, JJ; Chen, YP; Guo, YB; Hou, JL; Ma, SW; Peng, J; Wang, ZH, 2008) |
| "The main goal for treatment of chronic hepatitis B is to prevent complications such as liver cirrhosis or hepatocellular carcinoma." | ( Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J, 2008) |
| "Seventy-five patients with chronic hepatitis B were treated daily with an injection containing the same basic therapeutic drugs and randomly divided into a NAC group (50 patients) and a GSH group (25 patients)." | ( Guo, SH; Ren, H; Shi, XF; Wang, N; Zhang, DZ, 2008) |
| "Patients with severe exacerbation of chronic hepatitis B, sometimes developing into fulminant liver failure, are at high risk for mortality even with antiviral therapy." | ( Arai, M; Fujiwara, K; Fukai, K; Imazeki, F; Oda, S; Sadahiro, T; Suzuki, A; Suzuki, H; Yasui, S; Yokosuka, O; Yonemitsu, Y, 2008) |
| "Reactivation of chronic hepatitis B in HBsAg carriers is a well known complication of chemo?therapy." | ( Dumoulin, FL; Fischer, HP; Sauerbruch, T; Wasmuth, JC, 2008) |
| "Treatment of chronic hepatitis B (CHB) is difficult." | ( Canbakan, B; Erdem, L; Mert, A; Ozaras, R; Senturk, H; Tabak, F; Yurdakul, I, 2009) |
| "Treatment of chronic hepatitis B with oral nucleos(t)ide analogs is evolving rapidly with newer compounds gaining approval." | ( Hadziyannis, SJ; Vassilopoulos, D, 2008) |
| "Nine patients with lamivudine-resistant chronic hepatitis B infection who had been treated with adefovir 10 mg/day and had had a suboptimal response but did not have genotypic resistance to adefovir were treated with high-dose adefovir (20 mg/day)." | ( Colombo, M; Facchetti, F; Lampertico, P; Lunghi, G; Viganò, M, 2008) |
| "Thirty-six HbeAg positive chronic hepatitis B patients were recruited and received telbivudine treatment for 9 months." | ( Chen, M; Pan, XC; Yang, F, 2008) |
| "Evaluation of chronic hepatitis B virus patients for lamivudine resistance and planning the treatment accordingly may prevent complications and can increase the effectiveness of the treatment." | ( Akman, S; Elaldi, A; Köse, S; Tunçbilek, S, 2008) |
| "Patients with chronic hepatitis B (HBeAg+ and HBeAg-) randomized in two trials of adefovir (ADV) vs placebo, with available paired liver biopsies and FT-AT at baseline and after 48 weeks of treatment were included." | ( Benhamou, Y; Hadziyannis, S; Marcellin, P; Ngo, Y; Poynard, T; Ratziu, V, 2009) |
| "Patients with chronic hepatitis B (CHB) who will and those who will not respond to adefovir (ADV) monotherapy need to be identified at an early stage in order to adjust treatment and prevent future development of antiviral resistance." | ( de Man, RA; Hansen, BE; Janssen, HL; Leemans, WF; Pas, SD; Reijnders, JG; Schutten, M, 2009) |
| "Acute exacerbation (AE) of chronic hepatitis B virus (HBV) infection in cancer chemotherapy patients and in organ transplant recipients receiving immunosuppressants may cause catastrophe and high mortality." | ( Chen, JJ; Koay, LB; Kuo, HT; Lee, C; Lin, CY; Sheu, MJ; Tang, LY; Tsai, SL, 2009) |
| "In 11 chronic hepatitis B patients with lamivudine treated per day, the model with delay time was applied to examine phase transition and analyze viral kinetics parameters." | ( Cai, T; Lou, GQ; Yang, J, 2009) |
| "The treatment of chronic hepatitis B virus (HBV) infection has been revolutionized in the past decade by the increased availability of effective antiviral agents." | ( Nash, K, 2009) |
| "Fourteen chronic hepatitis B patients (57% lamivudine-experienced) with a viral load above 5log(10)copies/mL after 12months of adefovir therapy and thereafter were treated with entecavir 1mg daily." | ( de Man, RA; Janssen, HL; Pas, SD; Reijnders, JG; Schutten, M, 2009) |
| "Patients with chronic hepatitis B virus (HBV) infection who develop antiviral resistance lose benefits of therapy and may be predisposed to further resistance." | ( Baldick, CJ; Colonno, RJ; Eggers, BJ; Fang, J; Pokornowski, KA; Rose, RE; Tenney, DJ; Wichroski, MJ; Wilber, RB; Xu, D; Yang, J, 2009) |
| "A total of 97 chronic hepatitis B (CHB) patients with YMDD mutants who had been treated with ADV for >12 months were analysed." | ( Chung, YH; Kim, JA; Kim, KM; Kim, SE; Lee, HC; Lee, YS; Lim, YS; Park, NH; Shin, JW; Suh, DJ, 2009) |
| "The immune response of patients with chronic hepatitis B is improved to some extent after LDT therapy." | ( Chen, M; Guo, SH; He, H; Zhang, DZ; Zhang, L, 2009) |
| "Long-term management of some chronic hepatitis B patients might require combination therapy using drugs with distinct resistance profiles to sustain viral suppression and to reduce the resistance-associated failure." | ( Borroto-Esoda, K; Curtis, M; Miller, MD; Qi, X; Zhu, Y, 2009) |
| "Diagnosis and treatment of chronic hepatitis B (CHB) have improved in recent years with introduction of new oral antiviral drugs." | ( Buti, M; Córdoba, J; Esteban, R; García-Martínez, R; Les, I; Quintana, M, 2009) |
| "Treatment options for chronic hepatitis B include pegylated interferon and 4 licensed oral nucleosides/nucleotides (lamivudine, adefovir entecavir and tenofovir)." | ( Buffet, C, 2008) |
| "Seventy-one chronic hepatitis B patients achieving seroconversion of hepatitis B e antigen (HBeAg) as well as effective maintained virological suppression during lamivudine therapy were included." | ( Chen, YC; Hsu, CW; Liaw, YF; Yeh, CT, 2009) |
| "A considerable number of chronic hepatitis B (CH-B) patients remain under continuous lamivudine treatment, although switching treatment to entecavir could be beneficial." | ( Doi, Y; Fukuda, K; Fukui, H; Hayashi, N; Hiramatsu, N; Imai, Y; Kanto, T; Kasahara, A; Kashihara, T; Kato, M; Kiso, S; Kurashige, N; Mita, E; Mochizuki, K; Nagase, T; Ohkawa, K; Oshita, M; Oze, T; Takehara, T; Yakushijin, T; Yamada, A; Yoshihara, H, 2009) |
| "Entecavir is effective and safe for the chronic hepatitis B patients failed with lamivudine therapy." | ( LI, H; REN, H; SHI, XF; WANG, ZY; ZHANG, DZ; ZHOU, Z, 2009) |
| "We performed a cohort study of 290 chronic hepatitis B patients: 145 patients treated with 10 mg ADV and 145 patients unexposed to ADV at two community clinics, who were matched for age (+/-10 years), sex, and baseline eGFR." | ( Garcia, RT; Ha, NB; Levitt, BS; Nguyen, HA; Nguyen, KK; Nguyen, MH; Trinh, HN; Vu, AA, 2009) |
| "Seventy-six children with chronic hepatitis B who were seropositive for HBeAg were treated with lamivudine for at least 6 months." | ( Cho, SM; Choe, BH; Chu, MA; Kim, JM, 2009) |
| "HBeAg-positive adults with chronic hepatitis B, elevated serum alanine aminotransferase, and compensated liver disease were randomized to double-blind treatment for up to 96 weeks with entecavir 0." | ( Brett-Smith, H; Chang, TT; de Man, R; Gadano, A; Gish, RG; Lai, CL; Poordad, F; Tamez, R; Yang, J, 2010) |
| "A total of 170 naïve HBeAg-positive chronic hepatitis B patients were treated with a nucleoside/nucleotide analogues (NA), either lamivudine, adefovir, entecavir, or telbivudine, for at least 2 years and followed up for 1 more year." | ( Cong, M; Jia, J; Li, H; Liu, T; Ma, H; Ou, X; Ren, J; Wang, B; Wang, P; Wang, X; You, H, 2009) |
| "Thirty-one patients with chronic hepatitis B with HBV DNA > or = 10(4) copies/mL after 48 weeks of ADV monotherapy were included and received ADV plus LAM for 24 weeks." | ( Cao, J; Chen, EQ; Lei, BJ; Liu, L; Tang, H; Wang, JR; Wang, LC, 2010) |
| "61 pregnant chronic hepatitis B (CHB) patients were enrolled and 31 patients were treated by telbivudine 600 mg once daily, 30 patients in the control group were not received antiviral treatment." | ( Wang, L; Zhang, LJ, 2009) |
| "Clinical data of 233 chronic hepatitis B patients treated with lamivudine 100mg daily (91 patients were switched to Adefovir 10mg daily or Adefovir 10mg in combination with lamivudine 100mg daily) were retrospective." | ( Fu, J; Li, SG; Tan, B; Wen, FY; Wu, JL; Yang, XY; Zhou, HJ, 2009) |
| "53 patients with chronic hepatitis B were enrolled in this study, HBV DNA,HBV markers, ALT, AST, TBil, albumin in the serum were examined at 0, 3, 6, 12, 18 and 24 months after lamivudine treatment." | ( Cao, XX; Chen, YH; Li, J; Luo, YW; Qiu, LM; Ran, Y, 2009) |
| "A cohort of 101 patients with advanced chronic hepatitis B and elevated AFP values was treated with entecavir (ETV) or peginterferon-alpha2a." | ( Karayiannis, P; Liu, Z; Luo, K, 2010) |
| "e antigen negative chronic hepatitis B patients with baseline ALT is more than or equal to 5 ULN and HBV DNA less than 1000 copies/ml at 12 weeks after treatment have better virological response at 104 weeks after LAM treatment." | ( Chai, YY; Li, JG; Li, JX; Li, SF; Liu, MX; Niu, Q; Qin, HQ; Tian, SW; Wang, XY; Zhang, JQ; Zhao, LF, 2009) |
| "Treatment of chronic hepatitis B has shown a rapid development in the last years leading to a shift of treatment strategies from interferon to hepatitis B virus (HBV)-polymerase inhibitors." | ( Mauss, S, 2009) |
| "Forty chronic hepatitis B patients who developed resistance after 3TC therapy were retrospectively enrolled." | ( Chen, DS; Chen, PJ; Hsieh, HL; Hsieh, TH; Kao, JH; Lai, MY; Liu, CJ; Tseng, TC, 2009) |
| "Current guidelines for management of chronic hepatitis B recommend treatment for patients presenting with elevated hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) >2 x upper limit of normal (ULN) or histological evidence of liver disease." | ( Chang, TT; Chao, YC; Gordon, SC; Han, KH; Han, SH; Lai, CL; Neo, BL; Sievert, W; Tan, CK; Tanwandee, T; Wu, IC; Xu, D, 2010) |
| "In adefovir (ADV) treated chronic hepatitis B patients carrying rtA181T/rtA181V mutations, overlap with surface gene mutations such as sW172stop/sL173F has been reported." | ( Bak, YT; Byun, KS; Joo, MK; Jung, YK; Kim, JH; Kim, JS; Park, JJ; Yeon, JE; Yim, HJ, 2010) |
| "Since its approval for the treatment of chronic hepatitis B in 1998, lamivudine (LAM) has been used extensively throughout the world, because of its relatively low costs and favourable tolerability." | ( Marcellin, P; Piratvisuth, T; Sung, J, 2010) |
| "The recommended therapy for chronic hepatitis B in children is still monotherapy with interferon alfa or lamivudine." | ( Jaklin Kekez, A, 2009) |
| "Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients are at high risk of treatment relapse after any antiviral therapy." | ( Akdogan, M; Cakaloglu, Y; Ferenci, P; Hansen, BE; Janssen, HL; Ormeci, N; Raptopoulou-Gigi, M; Rijckborst, V; Simon, K; Tabak, F; ter Borg, MJ; van Vuuren, AJ; Verhey, E; Zondervan, PE, 2010) |
| "Overall, 138 HBeAg-negative chronic hepatitis B patients were randomized to receive monotherapy (peginterferon alpha-2a 180 microg weekly plus placebo) or combination therapy (peginterferon alpha-2a weekly plus ribavirin 1,000 or 1,200 mg daily, depending on body weight) for 48 weeks." | ( Akdogan, M; Cakaloglu, Y; Ferenci, P; Hansen, BE; Janssen, HL; Ormeci, N; Raptopoulou-Gigi, M; Rijckborst, V; Simon, K; Tabak, F; ter Borg, MJ; van Vuuren, AJ; Verhey, E; Zondervan, PE, 2010) |
| "Therapy of chronic hepatitis B has improved by the invention of the potent nucleos(t)ide analogues entecavir, telbivudine and tenofovir disoproxil." | ( Bock, T; Karlas, T; Krasselt, U; Mössner, J; Schiefke, I; Tillmann, HL; Wiegand, J, 2010) |
| "Abstract Asymptomatic chronic hepatitis B virus (HBV) carriers are at risk of developing complications of liver disease, but these patients are not recommended for treatment with antiviral drugs." | ( Ahmed, F; Akbar, SM; Al-Mahtab, M; Karim, F; Khan, SI; Rahman, S; Uddin, H, 2010) |
| "The medical records of 76 chronic hepatitis B patients treated for a least 6 months from October 2006 to October 2008 were reviewed retrospectively." | ( Chae, HB; Goo, JC; Hong, SP; Jeong, JI; Kim, BU; Kim, SO; Park, BC; Park, SM; Youn, SJ, 2010) |
| "Patients with chronic hepatitis B receiving LAM therapy for > or = 6 months were eligible for the study regardless of the presence of LAM resistance, HBeAg status or serum ALT levels." | ( Ahn, M; Dunn, SR; Hann, HW; Park, SY, 2010) |
| "Treatment of chronic hepatitis B with generic ADV was effective and well tolerated, but relapse may develop when treatment was discontinued." | ( Chen, XY; Ding, HG; Dong, PL; Min, J; Wang, DM; Zhang, B; Zhang, XM, 2009) |
| "Therapy for chronic hepatitis B with tenofovir disoproxil fumarate (TDF) and lamivudine (3TC) or emtricitabine (FTC) is currently recommended for HIV-HBV coinfection." | ( Avihingsanon, A; Bowden, S; Chang, JJ; Dore, GJ; Kerr, S; Lange, J; Lewin, SR; Matthews, GV; Napissanant, N; Piyawat, K; Ruxrungtham, K, 2010) |
| "In treatment-naive patients with chronic hepatitis B the first line therapy should be PeglFN-alpha2a monotherapy, and the first-line should be entecavir or tenofovir (highest potential for HBV replication suppression and high genetic barrier to resistance)." | ( Boroń-Kaczmarska, A; Cianciara, J; Flisiak, R; Gładysz, A; Halota, W; Juszczyk, J; Kryczka, W; Malkowski, P; Pawlowska, M; Simon, K, 2010) |
| "This was a retrospective study of chronic hepatitis B patients on lamivudine therapy who were followed for 3-mo with liver function tests and hepatitis B virus (HBV) DNA measurement." | ( Aung, MO; Dan, YY; Fernandes, M; Koay, E; Lee, GH; Lee, YM; Lim, LG; Lim, SG; Seet, BL; Sutedja, DS; Tan, C, 2010) |
| "The complex therapy of patients with chronic hepatitis B and lambliasis, using cycloferon and macmiror, provided stable effect, less frequent relapses oflambliasis and minimum side effects of the specific therapy." | ( Agaeva, SG; Goriacheva, LG; Kovalenko, AL; Lin'kov, IuN; Romantsov, MG, 2010) |
| "Sera from 37 HBeAg-positive chronic hepatitis B patients receiving 48-weeks PEG-IFN α-2a with (n = 20) or without (n = 17) an initial 12-weeks thymosin α-1 were obtained at baseline and at weeks 12, 24, 36, 48 (end of treatment), 56, 72, 84, and 96 (end of follow-up)." | ( Jung, EU; Kim, BH; Kim, W; Kim, YJ; Lee, HS; Lee, JH; Lee, YJ; Myung, SJ; Park, MH; Park, SJ; Roh, EY; Shin, Y; Song, EY; Sue, S; Yoon, JH, 2011) |
| "Serum samples of 199 chronic hepatitis B patients undergoing NA treatment from five hospitals in four northern cities of China were obtained between January 2007 and July 2009." | ( Abuduheilili, X; Dong, JP; Hou, CS; Jiao, XJ; Li, T; Li, XG; Liu, BM; Sun, XW; Wang, YH; Xu, J; Yan, CH; Yan, L; Yang, JX; Zhuang, H, 2010) |
| "80 patients with chronic hepatitis B received the antiviral therapy of adefovir dipivoxil (ADV, 10 mg/d)." | ( Cao, H; Chen, LB; Li, G; Shu, X; Xie, QF; Xu, QH; Xu, Z, 2010) |
| "First-line treatment options for chronic hepatitis B (CHB) consist of nucleos(t)ide analogues with a high barrier to resistance (entecavir and tenofovir) or the immunomodulatory agent peginterferon (PEG-IFN)." | ( Janssen, HL; Rijckborst, V; Sonneveld, MJ, 2011) |
| "Current agents used in the treatment of chronic hepatitis B (CHB) can be classified into interferons-α (IFN-α: standard or pegylated) and nucleos(t)ide analogues (NUCs)." | ( Papatheodoridis, GV, 2011) |
| "Major progress in the treatment of chronic hepatitis B (CHB) has been made during the last decade with the development of antivirals that inhibit viral polymerase activity." | ( Zoulim, F, 2011) |
| "During treatment of patients with chronic hepatitis B the best therapeutic effect was obtained with the inclusion in the scheme of antiviral therapy cycloferon." | ( Goriacheva, LG; Kovalenko, AL; Lin'kova, IuN; Romantsov, MG; Shul'diakov, AA; Sologub, TV, 2010) |
| "Forty-five HBeAg-positive chronic hepatitis B patients with a virologic response [negative PCR (<12 IU/ml)] who had discontinued therapy were analyzed retrospectively for VR, HBeAg reversion and biochemical flare." | ( Cho, HC; Choi, MS; Gwak, GY; Kim, KH; Koh, KC; Lee, JH; Lee, YY; Paik, SW; Sinn, DH; Yoo, BC; Yun, WK, 2011) |
| "An increasing number of patients with chronic hepatitis B infection are being treated with the newly licensed drug, adefovir." | ( Chattopadhyay, P; Sarma, N, 2011) |
| "The use of cycloferon in the therapy of chronic hepatitis B made it possible to lower the frequency and manifestation level of the side effects and prevented the lamivudine resistance development and generation of the virus mutants." | ( Baranova, IP; Goriacheva, LG; Kovalenko, AL; Lin'kova, IuN; Romantsov, MG; Shul'diakov, AA; Sologub, TV, 2010) |
| "Treatment-naive patients with chronic hepatitis B (CHB) who were taking ETV for 2 years were enrolled." | ( Ahn, SH; Chang, HY; Chon, CY; Han, KH; Hwang, SG; Kim, DY; Kim, HS; Lee, JM; Park, H; Park, JY; Rim, KS, 2011) |
| "Treatment of chronic hepatitis B prolongs patients' overall survival and quality-adjusted life." | ( Mickevičienė, A; Padaiga, Z; Vanagas, G, 2010) |
| "A 46-year-old female patient with chronic hepatitis B had persistent detectable HBV DNA and positive serum hepatitis B e antigen (HBeAg), even while on long-term lamivudine and adefovir therapy." | ( Chen, CH; Chiang, LT; Ko, BS; Yao, M, 2011) |
| "Treatment of chronic hepatitis B is still challenging." | ( Tornai, I, 2011) |
| "The effect of chronic hepatitis B (CHB) treatment on hepatocyte apoptosis has not been evaluated." | ( Georgiou, A; Giannousis, IP; Hadziyannis, E; Manolakopoulos, SG; Papatheodoridis, GV, 2011) |
| "In this randomised study, chronic hepatitis B patients with lamivudine resistance were treated with peginterferon alfa-2a for 48 weeks (n=155) or adefovir for 72 weeks (n=80)." | ( Chan, HL; Chen, SJ; Hou, JL; Jia, JD; Jiang, M; Lai, JY; Li, MK; Li, XH; Popescu, M; Sheng, JF; Sun, J; Sung, JJ; Wang, H; Wang, JF; Wang, YM; Xie, Q; Zhang, JM, 2011) |
| "Sixty-five HBeAg-positive naïve chronic hepatitis B patients who were treated with entecavir at a dose of 0." | ( Chen, TY; Chen, YR; Lin, SM; Liu, M; Ye, F; Zhang, SL; Zhang, X; Zhao, YR; Zheng, SQ, 2011) |
| "Therapy of chronic hepatitis B with HBV-polymerase inhibitors, in particular tenofovir or adefovir, may affect renal function." | ( Athmann, C; Berger, F; Filmann, N; Hegener, P; Henke, J; Herrmann, E; Hueppe, D; Mauss, S; Schmutz, G, 2011) |
| "An increasing number of patients with chronic hepatitis B (CHB) have experienced treatment failure to adefovir (ADV) and their management poses a growing challenge." | ( Do, ST; Garcia, RT; Nguyen, HA; Nguyen, KK; Nguyen, MH; Nguyen, TT; Sheen, E; Tran, P; Trinh, HN, 2011) |
| "Before tenofovir approval for chronic hepatitis B therapy, the clinical management of patients with suboptimal response or virological breakthrough during combination treatment with lamivudine and adefovir dipivoxil was a difficult clinical challenge." | ( Aldini, R; Azzaroli, F; Buonfiglioli, F; Galli, S; Giandinoto, M; Lisotti, A; Mazzella, G; Montagnani, M; Turco, L, 2012) |
| "We enrolled 231 nucleoside-naïve chronic hepatitis B (CHB) patients primarily treated with entecavir 0." | ( Jin, YJ; Kim, KM; Lee, HC; Lim, YS; Shim, JH; Suh, DJ; Yoo, DJ, 2011) |
| "The management of chronic hepatitis B currently rests with long-term therapy using nucleoside analogs." | ( Halota, W; Pawłowska, M, 2011) |
| "In total, 33 patients with chronic hepatitis B virus (HBV) infection with evidence of active viral replication (HBV DNA levels ≥ 10(5) copies/mL) or a history of treatment failure to lamivudine/adefovir sequential therapy between April 2007 and July 2009 were treated with entecavir (1." | ( Cho, YS; Choi, JW; Kim, KA; Kwak, MS; Lee, CK; Lee, JS; Park, BK; Suh, JH; Won, SY, 2011) |
| "To determine the clinical outcome of chronic hepatitis B cirrhotics on antiviral therapy." | ( Aung, MO; Dan, YY; Fernandes, M; Lai, V; Lee, GH; Lee, YM; Lim, SG; Low, HC; Mak, B; Sutedja, D, 2011) |
| "A large clinic cohort of chronic hepatitis B cirrhotic patients were enrolled in a treatment program of lamivudine ± adefovir therapy." | ( Aung, MO; Dan, YY; Fernandes, M; Lai, V; Lee, GH; Lee, YM; Lim, SG; Low, HC; Mak, B; Sutedja, D, 2011) |
| "Decompensated chronic hepatitis B cirrhotics may suffer early mortality despite antiviral treatment, and therefore should be considered for early liver transplantation." | ( Aung, MO; Dan, YY; Fernandes, M; Lai, V; Lee, GH; Lee, YM; Lim, SG; Low, HC; Mak, B; Sutedja, D, 2011) |
| "To optimize Adefovir therapy in chronic hepatitis B (CHB) patients with hepatitis B e antigen (HBeAg) positive, we studied the baseline parameters and on-treatment HBV DNA for favorable outcomes." | ( Geng, da Y; Lu, B; Lu, H; Ma, LX; Shen, F; Zhang, JY, 2011) |
| "To study the effect of Lamivudine on chronic hepatitis B patients with chemotherapy or immunosuppressive agents therapy, and research the drug resistance." | ( Li, DJ; Liu, C; Liu, L; Lu, LX; Lu, XJ; Tang, H; Wang, LC; Wang, Y; Xu, KW, 2011) |
| "Thirty-one cases of chronic hepatitis B patients who needed chemotherapy or immunosuppressive agents therapy were enrolled and divided into two group, HBeAg-positive group (n = 20) and HBeAg-negative group (n = 11), then given Lamivudine for preventive treatment." | ( Li, DJ; Liu, C; Liu, L; Lu, LX; Lu, XJ; Tang, H; Wang, LC; Wang, Y; Xu, KW, 2011) |
| "For the chronic hepatitis B patients on initial treatment with lamivudine, the viral rebound occurred mainly within 2 years." | ( Chen, Y; He, LL; Lei, BJ; Lei, XZ; Xu, H, 2011) |
| "Patients with chronic hepatitis B were randomised to nine months treatment with PEG-IFNα-2b 1." | ( Berr, F; Brosteanu, O; Kullig, U; Maier, M; Schiefke, I; Tillmann, HL; Wiegand, J; Wiese, M, 2011) |
| "Monitoring therapy in chronic hepatitis B patients receiving lamivudine therapy, is done by two different assays; determination of viral load and genotypic resistance." | ( Ağca, H; Akarsu, M; Sayıner, AA; Sengönül, A; Simşek, I, 2011) |
| "This retrospective study enrolled 38 chronic hepatitis B patients treated with IFN-α plus a nucleos(t)ide analog who achieved HBsAg seroconversion during the period from June 2001 to May 2009." | ( Cao, Z; Chen, X; Jin, Y; Liu, Y; Ma, B; Ma, L; Wu, H; Yu, H; Zhang, H; Zhang, Y; Zheng, Y, 2012) |
| "The optimal treatment of patients with chronic hepatitis B (CHB) who develop resistance to both lamivudine (LMV) and entecavir (ETV) after sequential monotherapy of LMV and ETV remains little known." | ( Cha, JM; Jeon, JW; Joo, KR; Kim, S; Lee, JI; Lim, JU; Lim, K; Park, JJ; Shin, HP, 2012) |
| "for the therapy of chronic hepatitis B." | ( Chu, CK; Gadthula, S; Rawal, RK; Singh, US, 2011) |
| "A total of 559 chronic hepatitis B (CHB) patients who had been treated for at least 12 months with adefovir add-on therapy due to resistance to lamivudine were retrospectively included." | ( Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Paik, SW; Sinn, DH; Yoo, BC, 2012) |
| "In a cohort of 95 chronic hepatitis B patients, who were treated with peg-interferon and adefovir for 1 year, and who had 15% HBsAg loss (overall), no association was found between IL28B polymorphisms and HBeAg seroconversion or HBsAg clearance." | ( Beld, MG; Benayed, R; de Niet, A; Jansen, PL; Koot, M; Lopatin, U; Reesink, HW; Riley-Gillis, B; Takkenberg, RB; Weegink, CJ; Zaaijer, HL, 2012) |
| "Entecavir is an effective treatment for chronic hepatitis B." | ( Bonet, L; Buti, M; Diago, M; García-Samaniego, J; Morillas, RM; Palau, A; Pérez, J; Prieto, M; Rodríguez, M; Solà, R; Testillano, M, 2012) |
| "As rescue treatment for patients with chronic hepatitis B who had previously resisted LAM and failed with treatment of LAM + ADV, ETV + ADV was more efficient than ETV 1." | ( Han, T; Li, J; Li, Y; Liu, L; Xiao, SX; Xing, J, 2011) |
| "Patients with chronic hepatitis B with and without previous lamivudine therapy were randomised to receive adefovir alone (10 mg/daily) or adefovir and lamivudine (100 mg/daily) for up to 192 weeks." | ( Doo, E; Feld, JJ; Ghany, MG; Heller, T; Hoofnagle, JH; Kleiner, DE; Koh, C; Liang, TJ; Nagabhyru, P; Rotman, Y; Wright, EC; Zhao, X, 2012) |
| "Thus, when chronic hepatitis B patients show resistance or suboptimal response to ADV monotherapy, early modification of treatment should be considered." | ( Ahn, SH; Chon, CY; Han, KH; Kim, DY; Lee, JM; Lee, MH; Park, JY; Ryu, HJ; Son, CY, 2012) |
| "A total of 319 chronic hepatitis B patients who received lamivudine therapy for more than a year were enrolled in this study." | ( Wu, F; Wu, MJ; Zhu, B; Zhu, SM; Zhuge, XL, 2012) |
| "ETV is effective in treating chronic hepatitis B in RTRs." | ( Chang, KC; Chen, TC; Chen, YT; Chien, YS; Chiu, KW; Hu, TH; Lin, MT; Tsai, MC, 2012) |
| "Predictors of effective chronic hepatitis B therapy were described in that article." | ( Dybowska, D; Halota, W; Kozielewicz, D, 2012) |
| "We evaluated the first 12 months of chronic hepatitis B treatments with tenofovir and entecavir and compared their efficiencies." | ( Akin, MS; Doğan, ÜB; Gümürdülü, Y; Kara, B; Soylu, A, 2012) |
| "In the first year of treatment for chronic hepatitis B, virologic response and tolerability did not differ significantly between tenofovir and entecavir." | ( Akin, MS; Doğan, ÜB; Gümürdülü, Y; Kara, B; Soylu, A, 2012) |
| "Growing numbers of chronic hepatitis B (CHB) patients in the Asia-Pacific region have failed first-line therapy with low genetic barrier drugs." | ( Ahn, SH; Cho, M; Han, KH; Heo, J; Kim, DY; Lee, HJ; Park, JY; Park, SY; Seo, YS; Tak, WY; Um, SH; Yoon, KT, 2012) |
| "Partial virologic response (PVR) in chronic hepatitis B (CHB) patients during antiviral therapy is associated with an increased risk of occurrence of viral resistance and treatment failure." | ( Choe, WH; Kim, JH; Kim, KH; Ko, SY; Kwon, SY; Lee, CH; Seo, JW, 2012) |
| "Eighty-two patients with HBeAg-positive chronic hepatitis B (CHB) received ETV therapy for ≥3 years." | ( Bang, SJ; Eum, JB; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, SR; Lee, SH; Park, BR; Park, NH; Shin, JW, 2012) |
| "New insights into the treatment of chronic hepatitis B with relevance for clinical practice have been adopted in these concise, revised guidelines." | ( Baak, BC; Bakker, CM; Beuers, UH; Brouwer, JT; Buster, EH; Drenth, JP; Honkoop, P; Janssen, HL; Kerbert-Dreteler, MJ; Koek, GH; Tan, AC; van der Spek, BW; van Erpecum, KJ; van Hoek, B; van Nieuwkerk, KM; van Soest, H; Vrolijk, JM, 2012) |
| "Therefore, we compared chronic hepatitis B patients who received NA therapy to those who did not, using a propensity analysis." | ( Andou, Y; Hisanaga, Y; Kanamori, A; Kiriyama, S; Kumada, T; Niinomi, T; Tada, T; Tanaka, J; Tanikawa, M; Toyoda, H; Yamamoto, K; Yasuda, S, 2013) |
| "Sequential antiviral therapy for chronic hepatitis B may lead to the selection of multidrug-resistant mutation." | ( Choi, DJ; Jung, YK; Kim, JH; Kim, YS; Ku, YS; Kwon, OS, 2013) |
| "The patient cohort included four adult chronic hepatitis B patients who had undergone sequential monotherapy, first with lamivudine (LMV) and then, after developing viral breakthrough, with adefovir (ADV) therapy." | ( Choe, WH; Kim, BK; Kim, JH; Kim, KH; Ko, SY; Kwon, SY; Lee, CH, 2012) |
| "Patients with chronic hepatitis B virus (HBV) infection are at an increased risk for a severe and a potentially fatal viral reactivation following anti-cancer therapy." | ( Bar-Yishay, I; Ben-Yehoyada, M; Burdelova, EO; Fishman, S; Halpern, Z; Mouler Rechtman, M; Shlomai, A, 2013) |
| "Treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogs is often required over a prolonged period to achieve durable virologic suppression." | ( Buti, M; Petersen, J, 2012) |
| "Management of lamivudine-resistant chronic hepatitis B (CHB) remains challenging, as inappropriate choice of treatment may cause multidrug resistance." | ( Baik, SK; Chae, HB; Hong, SP; Kim, CW; Kim, JH; Kim, MY; Kim, YS; Lee, CD; Lee, JI; Lee, JW; Lee, MS; Park, CK; Park, SH; Seo, YS; Um, SH; Yim, HJ; Yoon, EL, 2013) |
| "In patients affected by chronic hepatitis because of HBV infection, long-term suppressive therapy with nucleos(t)ides analogues in the HBeAg- patients has shown low effects on HBsAg titre (qHBsAg) decrease, and HBsAg loss is difficult to achieve." | ( Baietto, L; Boglione, L; Burdino, E; Cariti, G; Cusato, J; D'Avolio, A; De Rosa, FG; Di Perri, G; Ghisetti, V; Gregori, G, 2013) |
| "Fifty patients with chronic hepatitis B without the loss of HBeAg after ≥96 weeks of lamivudine treatment were enrolled to withdraw from treatment to induce a biochemical breakthrough." | ( Mao, Q; You, JP; Zhang, HY; Zhang, XQ, 2013) |
| "The vast majority of chronic hepatitis B patients in this study achieved virologic response through prolonged entecavir therapy, with only 1." | ( Bang, SJ; Jeong, ID; Ju, HU; Jung, SW; Kim, BG; Kim, CJ; Kim, MH; Park, BR; Park, JH; Park, NH; Shin, JW, 2013) |
| "Currently available antiviral treatment for chronic hepatitis B virus infection can be divided into two classes of therapeutic agents: nucleos(t)ide analogues (NAs) and interferon (IFN)." | ( Enomoto, M; Kawada, N; Nishiguchi, S; Tamori, A, 2013) |
| "One hundred forty six patients with chronic hepatitis B treated with 30 mg of clevudine per day for 73 weeks (range, 36-132 weeks) were enrolled." | ( Choi, DJ; Jung, YK; Kim, JH; Kim, YS; Kwon, OS; Lee, JJ; Lee, JW; Lee, YJ, 2013) |
| "Consecutive chronic hepatitis B patients on telbivudine monotherapy were studied." | ( Chan, HL; Chan, HY; Cheung, CM; Lo, AO; Wong, GL; Wong, VW, 2013) |
| "A total of 45 chronic hepatitis B subjects were studied at baseline and were followed up on entecavir treatment." | ( Abraham, P; Eapen, CE; Ismail, AM; Kannangai, R; Kumar, MS; Sharma, OP, 2013) |
| "Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) is the most frequent and difficult-to-treat viral hepatitis worldwide." | ( Bonino, F; Brunetto, MR; Caputo, A; Coco, B; Espinos, B; Iannazzo, S; Latour, A; Rossetti, F, 2013) |
| "Three hundred and fifty-four naïve chronic hepatitis B (CHB) patients treated with lamivudine were enrolled in this study." | ( Liu, D; Liu, X; Ma, J; Ma, N; Wang, Y; Yu, F; Yuan, S; Zhang, X, 2013) |
| "The ideal approach to treat chronic hepatitis B remains controversial." | ( Hagiwara, S; Inoue, T; Inuzuka, T; Kudo, M; Matsumoto, A; Matsuo, H; Nishida, N; Osaki, Y; Sakurai, T; Tanaka, E; Ueshima, K; Yada, N, 2013) |
| "We enrolled 21 chronic hepatitis B patients who failed to respond to lamivudine therapy and were switched to entecavir treatment." | ( Deng, XL; Guo, JJ; Li, QL, 2013) |
| "We investigated 487 chronic hepatitis B patients (323 NA-naive, 164 NA-experienced) treated with entecavir monotherapy for at least 12 months." | ( Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH; Yang, SC, 2013) |
| "We treated 92 chronic hepatitis B patients (44 hepatitis B e antigen [HBeAg]-positive and 48 HBeAg-negative) with HBV DNA > 100,000 copies/ml (> 17,182 IU/ml) with PEG-IFN and adefovir for 48 weeks and followed them up for 2 years." | ( Beld, MG; de Niet, A; Dijkgraaf, MG; Jansen, L; Jansen, PL; Janssen, HL; Koot, M; Molenkamp, R; Reesink, HW; Rijckborst, V; Takkenberg, RB; Terpstra, V; Weegink, CJ; Zaaijer, HL, 2013) |
| "Should treatment of chronic hepatitis B virus infection be necessary during pregnancy, tenofovir, listed by the FDA as pregnancy category B drug, is to be preferred." | ( Horváth, G, 2013) |
| "647 patients with HBeAg positive chronic hepatitis B who have not previously received antiviral therapy were participated in randomized, post-marketing, double-blinded, placebo-controlled clinical trial." | ( Oiungerel, M; Okovityĭ, SV; Romantsov, MG; Stel'makh, VV; Tuan, NKh, 2013) |
| "One major challenge in the treatment of chronic hepatitis B is to maintain long-term viral suppression without promoting the selection of drug-resistant mutations." | ( Borroto-Esoda, K; Corsa, A; Flaherty, J; Kitrinos, KM; Liu, Y; Marcellin, P; Miller, MD; Snow-Lampart, A, 2014) |
| "Twenty-six chronic hepatitis B patients who received ETV monotherapy for LMV resistance were enrolled." | ( Guo, JJ; He, S; Li, QL; Zhang, Y, 2013) |
| "Serum samples from chronic hepatitis B patients with virologic breakthrough during enticavir therapy were studied." | ( Guo, XF; Liu, Y; Luo, X; Wu, F; Zhang, CX, 2013) |
| "Twenty-one consecutive chronic hepatitis B patients experiencing severe acute exacerbation were treated with either telbivudine or entecavir." | ( Chang, MY; Chen, YC; Hsu, CW; Yeh, CT, 2013) |
| "Here we report the first case of chronic hepatitis B developing severe refractory LA during telbivudine monotherapy." | ( Hu, P; Huang, XY; Jin, JL; Lu, JH; Luo, SS; Weng, XH; Zhang, JM, 2013) |
| "For HBeAg positive chronic hepatitis B patients with high serum hepatitis B viral loads, combination treament of Peginterferon alpha-2a with entecavir is more effective than Peginterferon alpha-2a monotherapy in virologic response and ALT normalization after 24 weeks of treatment." | ( Chen, CT; Li, SX; Lin, YM; Liu, J; Liu, Y; Liu, YX; Yao, SM; Yuan, J; Zeng, W; Zhang, Y; Zhao, MF; Zhou, BP, 2013) |
| "Patients with chronic hepatitis B treated with tenofovir or entecavir were included in this retrospective study." | ( Akkoyunlu, Y; Ceylan, B; Eren, G; Fincanci, M; Muderrisoglu, C; Tozalgan, U; Yardimci, C, 2013) |
| "The treatment of chronic hepatitis B (CHB) in patients with chronic kidney disease (CKD) is based on nucleoside (lamivudine, telbivudine, entecavir) or nucleotide (adefovir, tenofovir) analogues (NAs), but it may be complex and the information is scarce." | ( Cholongitas, E; Papatheodoridis, G; Pipili, C, 2014) |
| "A total of 161 patients with chronic hepatitis B refractory to to combined therapy with lamivudine (LAM) and ADV were randomized to receive INFα-2b monotherapy (5×10(6), three times a week) (group A) or combined therapy with entecavir (0." | ( Chen, Z; Li, M; Liu, Z; Wu, J; Xu, G; Zhang, Q, 2013) |
| "The aim of chronic hepatitis B (CHB) antiviral therapy is to persistently suppress HBV and improve survival by preventing the progression of liver damage to cirrhosis, end-stage liver disease or hepatocellular carcinoma (HCC), thus preventing early liver-related death." | ( Lampertico, P; Mangia, G; Viganò, M, 2014) |
| "The goal of chronic hepatitis B (CHB) treatment is to achieve seroclearance of HBsAg." | ( Esteban, R; Pérez-Cameo, C; Pons, M, 2014) |
| "A total of 108 ACLF of HBeAg-negative chronic hepatitis B patients with different ACLF severity score were treated with internal general treatment added Entecavir." | ( Cao, H; Ke, WM; Mai, L; Yan, Y; Zhang, SQ, 2013) |
| "The serum samples from a chronic hepatitis B (CHB) patient firstly received LMV mono therapy and then switched to LMV + ADV combined therapy were also dynamically analyzed for 10 times." | ( Chen, H; Chen, J; Jiang, L; Li, D; Lin, J; Ou, Q; Su, M; Wang, W; Yang, B; Zeng, Y, 2014) |
| "The first choice of therapy in chronic hepatitis B infection can be pegylated interferon for 48 weeks or continuous entecavir or tenofovir therapy." | ( Gervain, J; Horváth, G; Hunyady, B; Lengyel, G; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I, 2014) |
| "Understanding the natural course of chronic hepatitis B virus (HBV) infection is very important for the management and treatment of chronic hepatitis B in children." | ( Choe, BH; Choe, HJ, 2014) |
| "Study was carried out among 175 chronic hepatitis B patients treated with LMV." | ( Flisiak, R; Jaroszewicz, J; Kowalczuk, O; Lapiński, TW; Nikliński, J; Parfieniuk-Kowerda, A; Trzos, A, 2013) |
| "A total of 188 naive chronic hepatitis B patients (83 HBeAg-positive, 105 HBeAg-negative patients), who were previously treated with lamivudine (treatment duration: 89." | ( Changchien, CS; Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH, 2014) |
| "Thirty-six HBeAg-positive patients with chronic hepatitis B (CHB) were enrolled for 52-week telbivudine monotherapy and were followed at treatment week (TW)-0, 4, 12, 24 and 52." | ( Jia, M; Jiang, W; Li, J; Li, L; Liu, Y; She, W; Wang, J, 2015) |
| "Fifteen HBeAg-positive chronic hepatitis B (CHB) patients were treated with adefovir dipivoxil." | ( Chen, J; Chen, LH; Dong, J; Gao, LY; Jiang, JJ; Liu, YR; You, J; Zeng, DW; Zheng, Q; Zhu, YY, 2014) |
| "Current treatment options for chronic hepatitis B (CHB) are nucleoside or nucleotide analogues and pegylated interferons." | ( Cagatay, A; Ceylan, B; Erdem, L; Gokturk, K; Gunduz, A; Karaosmanoglu, H; Kocak, F; Mete, B; Ozaras, R; Ozgunes, N; Senates, E; Tabak, F, 2014) |
| "Two hundred eighty patients with chronic hepatitis B virus (HBV) infection and lamivudine resistance (confirmed by INNO-LiPA Multi-DR) were randomly assigned (1:1) to groups treated with TDF or FTC/TDF." | ( Corsa, AC; Flaherty, JF; Fung, SK; Gane, E; Kitrinos, KM; Liu, Y; Miller, MD; Mitchell, B, 2014) |
| "In a study of 266 chronic hepatitis B e antigen (HBeAg)-positive patients, 23 experienced hepatitis B surface antigen (HBsAg) loss with up to 5 years of tenofovir disoproxil fumarate (TDF) treatment." | ( Buti, M; de Man, RA; Dinh, P; Dusheiko, GM; Flaherty, JF; Flisiak, R; Gaggar, A; Gurel, S; Heathcote, EJ; Krastev, Z; Lin, L; Lou, L; Marcellin, P; Massetto, B; McHutchison, JG; Subramanian, GM; Zeuzem, S, 2014) |
| "The treatment of HBeAg-negative chronic hepatitis B (CHB) is considered to be open-ended, with no guidelines for treatment cessation." | ( Afdhal, NH; Bonder, A; Lau, D; Patwardhan, VR; Sengupta, N, 2014) |
| "Ideal nucleos(t)ide analog therapy in chronic hepatitis B patients with kidney transplantation must ensure virological suppression and minimize renal injury." | ( Shan, C; Wu, P; Yin, GQ, 2014) |
| "A 50-year-old Chinese man with chronic hepatitis B and kidney transplantation received nucleos(t)ide analog therapy with sequential monotherapy and combination therapy." | ( Shan, C; Wu, P; Yin, GQ, 2014) |
| "TDF-treated patients with chronic hepatitis B have reduced bone mineral density, but the reduction is limited to 1 anatomical site." | ( Al-Shamma, S; Barr, DA; Burke, K; Foster, GR; Gill, US; Kallis, YN; Kennedy, PT; Kooner, P; Marley, RT; McPhail, MJ; Zissimopoulos, A, 2015) |
| "The treatments for chronic hepatitis B (CHB) are interferon and nucleoside analogues reverse transcriptase (RT) inhibitors." | ( Enomoto, M; Hayakawa, M; Iwadate, M; Kawada, N; Murakami, Y; Tamori, A; Tanahashi, T; Umeyama, H; Yano, Y, 2015) |
| "Treatment-naïve chronic hepatitis B patients receiving besifovir 90 mg (n=31), 150 mg (n=28) and entecavir 0." | ( Ahn, SH; Cho, M; Han, KH; Kim, JA; Kweon, YO; Lai, CL; Lee, J; Lee, JW; Lee, KS; Park, NH; Sohn, JH; Um, SH; Yoon, SK; Yuen, MF, 2015) |
| "Fifty-seven patients of chronic hepatitis B on rescue treatment with TDF were analyzed retrospectively." | ( Fan, H; Fan, Y; Ge, Y; Li, D; Liu, X; Liu, Z; Lyu, W; Yang, H; Zhou, B, 2014) |
| "In patients with chronic hepatitis B, the use of antiviral treatment was associated with favorable overall survival after sorafenib therapy (HR 0." | ( Ahn, JM; Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Lim, HY; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC, 2015) |
| "Current agents for the treatment of chronic hepatitis B (CHB) can be classified into interferon-α (standard or pegylated) (IFN) and nucleos(t)ide analogues (NAs)." | ( Papatheodoridis, GV; Vlachogiannakos, J, 2015) |
| "Of the 199 treatment-naive chronic hepatitis B patients, 141 (70." | ( Aktuğ Demir, N; Kölgelier, S; Özçimen, S; Sümer, Ş, 2014) |
| "There were 136 patients of chronic hepatitis B treated with entecavir (68) or telbivudine (68)." | ( He, M; Li, DJ; Liu, C; Lu, JJ; Lu, LX; Tang, H; Wang, LC; Wang, WZ, 2014) |
| "The goal of treatment for chronic hepatitis B (CHB) is now to improve quality of life and to prevent the poor outcomes of the disease rather than to eliminate the virus from the body." | ( Abdurakhmanov, DT; Otrashevskaya, AV, 2014) |
| "Twenty-two patients with chronic hepatitis B were enrolled; three of them were previously treated with NAs and 19 were NAs-naïve treated." | ( Armendáriz-Borunda, J; Bobadilla-Morales, L; Bueno-Topete, M; Fernández-Galindo, DA; Gómez-Quiróz, P; Sánchez-Ávila, F; Sánchez-Orozco, LV, 2015) |
| "Patients with chronic hepatitis B (HBV DNA load, >17 000 IU/mL) were treated with pegylated interferon alfa-2a and adefovir for 48 weeks." | ( de Niet, A; Jansen, L; Kootstra, NA; Reesink, HW; Stelma, F; Takkenberg, RB; Tempelmans Plat-Sinnige, MJ; van Leeuwen, EM, 2015) |
| "Differences between patients with chronic hepatitis B with HBsAg clearance and nonresponders suggest that NK cells play a role in the clearance of HBsAg during interferon-based combination therapy." | ( de Niet, A; Jansen, L; Kootstra, NA; Reesink, HW; Stelma, F; Takkenberg, RB; Tempelmans Plat-Sinnige, MJ; van Leeuwen, EM, 2015) |
| "Current therapies of chronic hepatitis B (CHB) remain limited to either pegylated interferon-α (Peg-IFN-α), or one of the five approved nucleoside analog (NA) treatments." | ( Durantel, D; Zoulim, F, 2015) |
| "We enrolled 165 patients with chronic hepatitis B infection who were treated with ADV monotherapy (n = 90) or ADV plus lamivudine combination therapy (n = 75)." | ( Cai, H; Chen, JY; Ding, F; Hu, JH; Jia, HY; Li, LJ; Lian, JS; Lu, YF; Xiang, DR; Yang, YD; Yu, GD; Yu, L; Zeng, LY; Zhang, YM; Zheng, L, 2015) |
| "It is unclear whether patients with chronic hepatitis B with partial response to entecavir (ETV) who have achieved complete viral suppression (CVS) with ETV plus tenofovir (TDF) combination therapy maintain CVS if switched to TDF or ETV." | ( Chaung, KT; Ha, NB; Kim, LH; Kin, KC; Nguyen, HA; Nguyen, MH; Trinh, HN; Vu, VD, 2015) |
| "Thirty-six patients with chronic hepatitis B and 24 healthy individuals were selected as the experimental and control groups, respectively, and the serum levels of MIF, IL-17, and IL-10 were measured during the period in which the experimental group was treated with oral Baraclude(®); meanwhile, the alanine aminotransferase (ALT), hepatitis B virus (HBV) DNA, and HBV marker (M) levels were measured in the experimental group." | ( Chen, T; Li, XY; Yu, XH; Zhang, JC, 2015) |
| "In the past decade, many chronic hepatitis B (CHB) patients have undergone sequential treatment with lamivudine (LAM), adefovir (ADV), and entecavir (ETV) to manage antiviral resistance or insufficient suppression of HBV-DNA." | ( Bang, SJ; Jeong, ID; Jung, SW; Kim, BG; Kim, CJ; Kim, EH; Kim, JH; Kim, MH; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW; Sung, SJ, 2015) |
| "Viral genotype shift in chronic hepatitis B (CHB) patients during antiviral therapy has been reported, but the underlying mechanism remains elusive." | ( Chen, J; Gong, X; Huang, A; Huang, W; Liang, Z; Shan, X; Shan, Y; Wang, Y; Xu, G; Zen, A; Zhang, D; Zhang, X; Zhao, Y; Zhou, X, 2015) |
| "We reviewed 167 lamivudine-resistant chronic hepatitis B patients who received adefovir add-on rescue therapy for up to 5 years." | ( Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, SB; Kim, SU; Park, JY, 2016) |
| "Treatment of patients with chronic hepatitis B (CHB) with nucleos(t)ide analogues (NAs) suppresses hepatitis B virus (HBV) DNA production but does not affect the synthesis of the RNA pregenome or HBV messenger RNA." | ( Jansen, L; Kootstra, NA; Reesink, HW; Takkenberg, RB; van Dort, KA; Zaaijer, HL, 2016) |
| "To compare renal function in chronic hepatitis B (CHB) patients before and after antiviral treatment with either telbivudine or entecavir administered as monotherapy,as well as to assess the impact of these antivirals on renal function in patients with mild renal impairment and to provide evidence for optimizing each as an antiviral treatment of CHB." | ( Li, W; Zhang, D, 2015) |
| "To compare the histological outcome of chronic hepatitis B (CHB) patients treated with entecavir (ETV) or lamivudine (LAM)-based therapy." | ( Chen, JZ; Chen, SL; Du, XF; Hu, XQ; Shao, LY; Wang, J; Wang, JL; Weng, XH; Yu, YQ; Zhang, WH, 2015) |
| "Seventy-six HBeAg-positive chronic hepatitis B patients were randomly divided into two groups (n=38): group A was treated with interferon alpha-2a (IFN-α-2a) and group B was treated with peginterferon alpha-2a (peg IFN-α-2a)." | ( Dong, Z; Huang, Y; Li, B; Liu, S; Zheng, H, 2016) |
| "Twenty-six HBeAg-positive chronic hepatitis B patients were treated with LDT for a period of 104 weeks and were characterized as 16 responders, six partial responders and four viral breakthrough patients based on hepatitis B virus (HBV) DNA levels." | ( Deng, F; Du, R; Fang, W; Han, M; Hu, Z; Liu, J; Ning, Q; Rayner, S; Wang, H; Wang, M; Wu, C; Wu, Z; Yin, F, 2015) |
| "HBeAg negative chronic hepatitis B patients took 10mg adefovir dipivoxil capsules once daily, while positive chronic hepatitis B patients were randomly divided into either a treatment group or a control group." | ( Gu, J; Shen, S; Sun, R; Yu, Z, 2015) |
| "HBeAg positive chronic hepatitis B patients receiving ETV naïve-treatment were enrolled." | ( Hu, H; Hu, P; Liu, F; Ren, H; Wang, X; Zou, F, 2015) |
| "to evaluate adherence of patients with chronic hepatitis B initiated on entecavir as first-line treatment and to correlate adherence with effectiveness." | ( Bermejo Vicedo, T; Rodríguez Sagrado, MÁ; Romero Díaz-Maroto, V; Sánchez Cuervo, M, 2015) |
| "A total of 109 patients who had chronic hepatitis B and were receiving NA therapy were analyzed." | ( Arai, K; Honda, M; Kaneko, S; Kawaguchi, K; Mizukoshi, E; Nakamura, M; Oishi, N; Okada, H; Sakai, Y; Shimakami, T; Shirasaki, T; Terashima, T; Wang, X; Yamashita, T, 2016) |
| "Untreated chronic hepatitis B can lead to liver failure and/or liver cancer." | ( Dierberg, K; Hoffmann, CJ; Palmo, T; Solomon, S; Stevens, K; Wangchuk, T, 2016) |
| "Antiviral therapy for chronic hepatitis B (CHB) is often required for prolonged periods." | ( Chauhan, R; Kumar, M; Rooge, S; Sarin, SK; Singh, AK; Varshney, A, 2016) |
| "Treatment of chronic hepatitis B (CHB) with polymerase inhibitors is key to prevent disease flares and progression toward advanced liver disease." | ( Andini, R; Durante-Mangoni, E; Falco, E; Iossa, D; Maiello, C; Parrella, A; Ragone, E; Utili, R; Vitrone, M; Zampino, R, 2016) |
| "Eighty-one chronic hepatitis B patients with a viral load above 4 log 10 copies/ml and high levels of serum alanine aminotransferase were treated with ETV 0." | ( Song, J; Sun, M; Tan, G; Wang, J; Wu, X, 2016) |
| "A total of 47 chronic hepatitis B (CHB) patients treated with ETV monotherapy were included in this study." | ( Cao, Y; Li, MR; Xi, HL; Xu, XY; Zhang, RW; Zhang, XX; Zhang, Y, 2016) |
| "Nucleos(t)ide analogues (NUCs) for chronic hepatitis B treatment achieve high rates of viral suppression and are generally well tolerated." | ( Berg, T; Chan, HL; Janssen, HL; Lampertico, P; Schindler, R; Strasser, SI, 2016) |
| "One hundred and six chronic hepatitis B (CHB) patients (17 cirrhotics of Child class A/B) who received entecavir therapy (0." | ( Ray, G, 2016) |
| "The treatment of chronic hepatitis B infection (CHB) in children is still an area of great uncertainty." | ( Andreone, P; Bacchi Reggiani, ML; Badia, L; Bernardi, M; Comparcola, D; Cursaro, C; Fiorino, S; Galli, S; Grandini, E; Loggi, E; Maselli, S; Pavoni, M; Puggioli, C; Verucchi, G; Viale, P; Vukotic, R, 2017) |
| "One to 5 years of therapy of chronic hepatitis B with oral nucleoside analogues result in significant clinical improvements, but effects of more prolonged therapy are not well defined." | ( Auh, S; Ghany, MG; Hoofnagle, JH; Koh, C; Lau, DT; Lingala, S, 2016) |
| "To describe outcomes of chronic hepatitis B with long-term lamivudine therapy." | ( Auh, S; Ghany, MG; Hoofnagle, JH; Koh, C; Lau, DT; Lingala, S, 2016) |
| "Forty-two patients with chronic hepatitis B treated with lamivudine were followed for 3." | ( Auh, S; Ghany, MG; Hoofnagle, JH; Koh, C; Lau, DT; Lingala, S, 2016) |
| "Of the hepatitis B e antigen-negative chronic hepatitis B patients with more than 1 year of sustained hepatitis B virus (HBV) suppression during therapy, the 1-year clinical relapse rate after cessation of entecavir therapy was 45%, of which 25." | ( Chen, YC; Chien, RN; Hu, TH; Jeng, WJ; Liaw, YF; Lin, CL; Sheen, IS, 2016) |
| "A total of 49 cases with HBeAg-negative chronic hepatitis B were treated with interferon (IFN) or IFN treatment for 6 months added with lamivudine, and were followed up for at least 6 months." | ( Cao, LL; Chen, DW; Dong, Y; Gan, Y; Wang, FC; Wang, LM; Wang, P; Xu, ZQ; Yan, JG; Zhang, HF; Zhang, M; Zhu, SS, 2016) |
| "Data on all chronic hepatitis B patients treated with entecavir or tenofovir between 2005 and 2014 were entered prospectively." | ( Chitturi, S; Farrell, GC; Kaye, G; Ooi, M; Shadbolt, B; Teoh, NC; Truong, J, 2017) |
| "Thirty patients with chronic hepatitis B were enrolled and serum samples were collected at multiple time points during treatment with telbivudine (LdT)." | ( Dong, H; He, Y; Hou, J; Jin, W; Kang, H; Shen, Y; Sun, J; Wang, S; Zhao, G; Zhou, B; Zhu, Y, 2017) |
| "Another 16 patients with HBeAg-positive chronic Hepatitis B were enrolled, and entecavir was administrated at 0." | ( Gao, YQ; Gao, YT; Jiang, Y; Jin, SG; Li, M; Sun, XH; Zhang, X; Zhou, ZH; Zhu, XJ, 2016) |
| "In patients with chronic hepatitis B, tenofovir disoproxil fumarate (TDF) plus pegylated interferon (PEG-IFN) for 48-weeks results in higher rates of hepatitis B surface antigen (HBsAg) loss than either monotherapy." | ( Agarwal, K; Ahn, SH; Buti, M; Caruntu, FA; Chan, HL; Charuworn, P; Chuang, WL; Elkhashab, M; Flisiak, R; Foster, GR; Fung, S; Gaeta, GB; Hui, AJ; Idilman, R; Lee, CM; Lim, SG; Lin, L; Ma, X; Marcellin, P; Martins, EB; Mehta, R; Morano, L; Papatheodoridis, G; Petersen, J; Samuel, D; Strasser, SI; Tabak, F; Tak, WY; Wu, G; Yee, LJ, 2016) |
| "One thousand and nine treatment-naïve chronic hepatitis B (CHB) patients were evaluated for cumulative rates of virologic response, biochemical response, and entecavir mutations." | ( Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC, 2017) |
| "The subsequent maintenance therapy in chronic hepatitis B (CHB) patients after long-term viral replication suppression is still uncertain." | ( Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Lin, ZY; Yeh, ML; Yu, ML, 2016) |
| "Treatment uptake in chronic hepatitis B virus (HBV) infection is low in South Australia, and the cost-effectiveness of increasing treatment uptake rates in this population has not been assessed." | ( Chinnaratha, MA; Fraser, RJ; Kaambwa, B; Wigg, AJ; Woodman, RJ, 2017) |
| "Analysis of Caucasian chronic hepatitis B subjects treated with entecavir or tenofovir from the prospective, multicenter database CIBERHEP." | ( Acero, D; Aguirre, A; Buti, M; Calleja, JL; Comas, C; Crespo, J; de Cuenca, B; Esteban, R; Fernandez-Bermejo, M; García-Samaniego, J; Gutierrez, ML; Lens, S; Manzano, ML; Moreno, D; Moreno-Palomares, JJ; Pascasio, JM; Piqueras, B; Riveiro-Barciela, M; Rivero, M; Rodríguez, FG; Sánchez-Pobre, P; Suárez, E; Tabernero, D, 2017) |
| "The influence of chronic hepatitis B virus (HBV) infection on the efficacy of intensive immunosuppressive treatment (IST) of severe aplastic anaemia (SAA) patients remains unclear." | ( Cai, H; Cao, X; Chen, M; Duan, M; Han, B; Li, J; Wang, S; Xu, Y; Zhang, W; Zhao, Y; Zhou, D; Zhu, T; Zhuang, J, 2017) |
| "The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease progression." | ( Lim, YS, 2017) |
| "The treatments of chronic hepatitis B cannot totally cure the disease but can prevent its progression to hepatocellular carcinoma, decreasing the levels of both morbidity and mortality." | ( Basile, M; Cicchetti, A; Coretti, S; Drago, C; Ruggeri, M, 2017) |
| "In patients with chronic hepatitis B with a low viral load, combination treatment (peg-IFN plus adefovir and peg-IFN plus tenofovir) did not result in significant HBsAg loss compared with no treatment, which does not support the use of combination treatment in this population of patients." | ( Beuers, U; de Niet, A; Jansen, L; Koot, M; Kuiken, SD; Molenkamp, R; Reesink, HW; Stelma, F; Takkenberg, RB; van Nieuwkerk, CMJ; Verheij, J; Weijer, S; Willemse, SB; Zaaijer, HL, 2017) |
| "Treatment for chronic hepatitis B (CHB) is virtually absent in sub-Saharan Africa." | ( Aberra, H; Berhe, N; Desalegn, H; Gundersen, SG; Johannessen, A; Medhin, G; Stene-Johansen, K, 2017) |
| "A total of 95 patients with chronic hepatitis B being treated with NUCs were enrolled." | ( Chayama, K; Enomoto, H; Enomoto, M; Hino, K; Hiramatsu, N; Ikeda, F; Kagawa, T; Kanda, T; Kang, JH; Kurosaki, M; Matsumoto, A; Mine, T; Miyase, S; Morihara, D; Murata, K; Nagaoka, S; Nishiguchi, S; Okuse, C; Saito, S; Sakisaka, S; Shinkai, N; Suzuki, Y; Takaguchi, K; Tanaka, E; Tanaka, Y; Tsuge, M; Yatsuhashi, H; Yokosuka, O, 2018) |
| "Current treatments for chronic hepatitis B (CHB) include pegylated interferon alpha (PEG-IFN-α) which is an immune modulator, and nucleos(t)ide analogs (NAs) which directly inhibit HBV DNA polymerase." | ( Guo, H; Jiao, J; Liu, Z; Qi, W; Wang, J; Wang, X; Xu, Y; Yu, F; Zhao, P; Zhou, C, 2017) |
| "The clinical course of chronic hepatitis B (CHB) patients with partial virologic response (PVR) during tenofovir disoproxil fumarate (TDF) therapy remains unclear." | ( Bang, SJ; Du Jeong, I; Jung, SW; Kim, BG; Lee, BU; Park, BR; Park, JH; Park, NH; Shin, JW, 2017) |
| "In the chronic hepatitis B patients with interferon resistance, the combined administration of entecavir and adefovir dipivoxil can significantly improve liver function, hepatic fibrosis and MELD scores." | ( Chang, S; Chen, B; Qiu, L; Shen, F; Sun, Y; Wu, K; Yu, L, 2017) |
| "The patients with HBeAg-negative chronic hepatitis B(n=119) were randomly divided into treatment group(n=69) and control group(n=50)." | ( Du, WX; Wu, L; Ye, ZR, 2016) |
| "It is unclear whether chronic hepatitis B (CHB) patients with antiviral resistance, who achieve a complete virologic response (CVR) with tenofovir disoproxil fumarate (TDF) and nucleoside analogue (NUC) combination therapy, maintain CVR if switched to TDF monotherapy." | ( Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Park, JY; Song, JE, 2018) |
| "New therapies to treat chronic hepatitis B (CHB) are urgently needed." | ( Barry, V; Daffis, S; Delaney, WE; Fletcher, SP; French, DM; Huntzicker, E; Lanford, RE; Li, L; Mikaelian, I; Niu, C, 2018) |
| "We retrospectively recruited 143 chronic hepatitis B (CHB) patients without cirrhosis (39 HBeAg-positive and 104 HBeAg-negative patients) who were previously treated with TDF and had post-treatment follow-up for at least 6 months (median: 55, IQR 36-85 weeks)." | ( Chen, CH; Hsu, YC; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH, 2018) |
| "The study included 411 noncirrhotic chronic hepatitis B patients (148 hepatitis B e antigen (HBeAg)-positive and 263 HBeAg-negative patients) who were treated with lamivudine (n = 110) or entecavir (n = 301) with posttreatment follow-up of at least 12 months." | ( Chen, CH; Hu, TH; Hung, CH; Lee, CM; Lu, SN; Wang, JH, 2018) |
| "Patients with chronic hepatitis B who were discontinuing NUC therapy were prospectively enrolled." | ( Chen, CL; Chen, DS; Chen, PJ; Kao, JH; Liou, JM; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC, 2018) |
| "The clinical management of chronic hepatitis B virus (HBV) patients is based exclusively on virological parameters that cannot independently determine in which patients nucleos(t)ide-analogue (NUC) therapy can be safely discontinued." | ( Becht, E; Bertoletti, A; Cheng, Y; Foster, GR; Gill, US; Hansi, NK; Kao, JH; Kennedy, PT; Kunasegaran, K; Le Bert, N; Lim, SG; Newell, EW; Rivino, L; Su, TH; Tan, DZ; Tseng, TC, 2018) |
| "Therapy in chronic hepatitis B (chronic hepatitis B) patients aims at improving their survival by preventing disease progression to cirrhosis and its complications." | ( Belci, P; Collo, A; Durazzo, M; Fagoonee, S; Gariglio, V; Loreti, L; Magistroni, P; Parise, R, 2018) |
| "Treatment of chronic hepatitis B with entecavir or tenofovir leads to viral suppression in almost all patients." | ( Gadano, A; Marciano, S, 2018) |
| "Long-term treatment of chronic hepatitis B (CHB) with nucleos(t)ide analogues is often necessary to achieve durable viral suppression." | ( Buti, M; Esteban, R; Riveiro-Barciela, M, 2018) |
| "Caucasian patients with chronic hepatitis B with or without compensated cirrhosis who receive long-term entecavir or tenofovir therapy have excellent overall eight-year survival, which is similar to that of the general population." | ( Berg, T; Buti, M; Calleja, JL; Chi, H; Colombo, M; Dalekos, G; de la Revilla, J; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Keskın, O; Kourikou, A; Lampertico, P; Lehretz, M; Loglio, A; Manolakopoulos, S; Papatheodoridis, GV; Savvidou, S; Siakavellas, S; Sypsa, V; van Boemmel, F; Vlachogiannakos, I; Yurdaydin, C, 2018) |
| "She had initially been treated for chronic hepatitis B infection with lamivudine and tenofovir, complicated by portal hypertension and variceal bleeding that thrice required banding." | ( Lelei-Mailu, FJ; Mariara, CM, 2018) |
| "Current treatment options for chronic hepatitis B (CHB) are pegylated interferon alpha and nucleoside analogues (NAs)." | ( Hu, YK; Huang, YX; Jin, JL; Ying, Y; Zhang, JM; Zhang, WH, 2018) |
| "We investigated 21,182 patients with chronic hepatitis B receiving antiviral treatment." | ( Chan, HL; Lam, KL; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC, 2018) |
| "We divided chronic hepatitis B (CHB) patients who received NA therapy into two groups: 1) those who did not develop HCC during the follow-up period after NA therapy (no-HCC group) and 2) those who did (HCC group)." | ( Akutsu, N; Ariizumi, Y; Itoh, F; Iwabuchi, S; Kai, M; Kang, JH; Kitajima, H; Matsui, T; Matsumoto, N; Nakano, M; Nakase, H; Niinuma, T; Oikawa, R; Okuse, C; Otsubo, T; Sasaki, H; Sasaki, S; Sasaki, Y; Suzuki, H; Suzuki, M; Takagi, M; Takahashi, H; Takeba, Y; Tanaka, Y; Tokino, T; Tsutsumi, T; Wakasugi, H; Yamada, N; Yamamoto, E; Yamamoto, H; Yotsuyanagi, H, 2018) |
| "In lamivudine-refractory chronic hepatitis B (CHB) patients, discontinuation of lamivudine therapy may lead to loss of lamivudine-resistant hepatitis B virus (HBV) and reappearance of wide-type HBV as dominant strains, yet the underlying mechanism remains unclear." | ( Chen, J; Liu, J; Liu, T; Pan, M; Zhang, Q; Zhou, YH, 2018) |
| "Hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients who developed HBeAg seroconversion during NA treatment were studied." | ( Chan, FWS; Chan, HLY; Chan, KH; Chim, AML; Hui, AJ; Li, MKK; Loo, CK; Tse, CH; Wong, GLH; Wong, VWS, 2019) |
| "A large proportion of patients with chronic hepatitis B (CHB) in China do not respond to entecavir (ETV) treatment." | ( Li, X; Liu, X; Ren, G; Sun, D; Xu, H; Ye, H; Zhuang, Y, 2019) |
| "In treated patients with chronic hepatitis B (CHB) who have achieved complete viral suppression, it is unclear if functional cure as indicated by hepatitis B surface antigen (HBsAg) seroclearance confers additional clinical benefit." | ( Chan, HL; Lam, KL; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC, 2019) |
| "Immune-tolerant chronic hepatitis B (CHB) patients awaiting assisted reproduction (AR) are required to initiate antiviral therapy because of laboratory safety concerns." | ( Cai, LR; Chen, FS; Huang, Q; Li, DL; Li, YH; Wu, HC; Wu, ZX; Zeng, ZY; Zhang, SA; Zhou, XL, 2019) |
| "A total of 219 patients with chronic hepatitis B (CHB) who underwent hepatic venous pressure gradient (HVPG) and liver biopsy before antiviral therapy were recruited." | ( Baik, GH; Bang, CS; Choi, EY; Ham, YL; Kim, DJ; Kim, HJ; Kim, SY; Shin, SP; Suk, KT; Yang, YJ, 2020) |
| "One strategy to treat chronic hepatitis B virus (HBV) infection could be to increase the functions of virus-specific T cells." | ( Acerbi, G; Ahn, SH; Alfieri, A; Andreone, P; Barili, V; Boni, C; Brillo, F; Brunetto, MR; Cavallone, D; Coco, B; Cursaro, C; Ferrari, C; Fisicaro, P; Fung, S; Gaggar, A; Janssen, HLA; Joshi, A; Laccabue, D; Lau, AH; Ma, X; Mangia, A; Margotti, M; Massetto, B; Pedrazzi, G; Piazzolla, V; Rodell, TC; Rossi, M; Santoro, R; Subramanian, GM; Trinh, H; Vecchi, A; Woo, J; Yoon, SK; Yoshida, EM; Zhao, Y, 2019) |
| "61 HBeAg-positive chronic hepatitis B (CHB) patients treated with pegylated interferon alfa-2a alone or in combination with adefovir (10 mg/day) for 48 weeks were included in this retrospective analysis." | ( Chen, PD; Fan, QQ; Jia, W; Qi, X; Wang, T; Wen, X; Zhang, JM; Zhang, WH; Zhu, MQ, 2019) |
| "Antiviral treatment for chronic hepatitis B (CHB) is largely unavailable in sub-Saharan Africa; hence, little is known about the prognosis after initiating treatment in African CHB patients." | ( Aberra, H; Berhe, N; Desalegn, H; Gundersen, SG; Johannessen, A; Medhin, G; Mekasha, B, 2019) |
| "The aim of the treatment in chronic hepatitis B is to prevent progression to cirrhosis and liver cancer." | ( Aydın, N; Kırdar, S; Sayan, M; Yaşa, MH, 2019) |
| "Treatment of chronic hepatitis B virus (HBV) infection with entecavir suppresses virus replication and reduces disease progression, but could require life-long therapy." | ( Cao, W; Cheinquer, H; Chen, C; Chen, S; Chen, Y; Cheng, M; Cooney, EL; Duan, Z; Gao, Z; Gong, G; Han, KH; Han, T; Hann, HW; Hou, JL; Ji, Y; Jia, JD; Klinker, H; Lee, C; Lim, SG; Lin, S; Morozov, V; Niu, J; Peng, CY; Ren, H; Shang, J; Sheng, J; Sollano, JD; Streinu-Cercel, A; Sun, J; Tan, D; Tang, H; Tang, X; Tanwandee, T; Wang, YM; Wei, L; Xie, Q; Zhao, W, 2020) |
| "Functional cure is the major goal of chronic hepatitis B (CHB) therapy though few biomarkers predict this outcome." | ( Cloherty, G; Deerain, J; Gaggar, A; Hammond, R; Kitrinos, K; Leary, T; Locarnini, S; O'Donnell, T; Subramanian, M; Walsh, R; Wong, D; Yuen, L, 2019) |
| "A total of 535 non-cirrhotic chronic hepatitis B (CHB) patients undergoing either ETV (n = 358) or TDF (n = 177) treatment were enrolled." | ( Chen, CH; Hu, TH; Hung, CH; Lu, SN; Ma, TL; Wang, JH, 2019) |
| "In Caucasians with chronic hepatitis B, the risk of hepatocellular carcinoma after the first 5 years of entecavir or tenofovir therapy depends on age, baseline cirrhosis status and liver stiffness at year 5, which can provide simple and reliable risk scores for hepatocellular carcinoma prediction and surveillance beyond year 5." | ( Berg, T; Buti, M; Calleja, JL; Chi, H; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Keskin, O; Kourikou, A; Lampertico, P; Loglio, A; Lopez-Gomez, M; Manolakopoulos, S; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Van Boemmel, F; Veelken, R; Vlachogiannakos, J; Voulgaris, T; Yurdaydin, C, 2020) |
| "Long-term antiviral therapy (AVT) for chronic hepatitis B (CHB) reduces the risk of hepatocellular carcinoma (HCC)." | ( Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Kweon, YO; Lee, EJ; Lee, HA; Lee, HW; Lee, YR; Park, JY; Park, SY; Seo, YS; Shin, HJ; Tak, WY; Um, SH, 2020) |
| "Herein, two pregnant women with chronic hepatitis B are presented; one became pregnant while receiving tenofovir disoproxil fumarate and continued the treatment during pregnancy, the other discontinued tenofovir disoproxil fumarate treatment on her own due to conception, but restarted at 26 weeks of pregnancy." | ( Ergen, P; Yilmaz Karadağ, F, 2020) |
| "A recent study in Asian patients with chronic hepatitis B (CHB) reported that the incidence of hepatocellular carcinoma (HCC) was lower in patients treated with tenofovir disoproxil fumarate (TDF) than entecavir (ETV), but this finding remains controversial." | ( Berg, T; Buti, M; Calleja, JL; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Kourikou, A; Lampertico, P; Loglio, A; Lopez-Gomez, M; Manolakopoulos, S; Papatheodoridi, M; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Van Boemmel, F; Veelken, R; Vlachogiannakos, J; Yurdaydin, C, 2020) |
| "In a large cohort of Caucasians with chronic hepatitis B treated with entecavir (ETV) or tenofovir disoproxil fumarate (TDF) monotherapy, cumulative rates of hepatocellular carcinoma did not differ (up to 12 years)." | ( Berg, T; Buti, M; Calleja, JL; Dalekos, GN; Esteban, R; Galanis, K; Gatselis, N; Goulis, J; Hansen, BE; Idilman, R; Janssen, HLA; Kourikou, A; Lampertico, P; Loglio, A; Lopez-Gomez, M; Manolakopoulos, S; Papatheodoridi, M; Papatheodoridis, GV; Savvidou, S; Sypsa, V; Van Boemmel, F; Veelken, R; Vlachogiannakos, J; Yurdaydin, C, 2020) |
| "Patients with chronic hepatitis B receiving maintenance TDF therapy and exhibiting hepatitis B surface antigen (HBsAg) level > 800 IU/ml were divided into two arms." | ( Chayama, K; Enomoto, H; Enomoto, M; Hiramatsu, N; Ikeda, F; Ito, K; Kagawa, T; Kanda, T; Kang, JH; Kondo, Y; Masaki, T; Matsui, T; Matsumoto, A; Miyase, S; Morihara, D; Murata, K; Nagaoka, S; Nishiguchi, S; Okuse, C; Saito, S; Shinkai, N; Takaguchi, K; Tanaka, E; Tanaka, Y; Tsuge, M; Yamada, R; Yatsuhashi, H, 2020) |
| "Treatment-naïve patients with chronic hepatitis B (CHB) receiving entecavir 0." | ( Ahn, SH; Chon, YE; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Lee, HA; Lee, HW; Min, IK; Park, JY; Park, SY; Seo, YS; Tak, WY, 2020) |
| "We enrolled treatment-naïve chronic hepatitis B (CHB) and HBV-related liver cirrhosis (LC) patients treated with ETV for 24 months." | ( Cheng, LS; Jiang, W; Li, J; Liu, Y; She, WM; Shen, Y; Wang, SQ; Wu, SD, 2021) |
| "To evaluate the impact of chronic hepatitis B virus infection (CHB) treatment on risk of cirrhosis, liver-related outcomes, and death among a diverse CHB cohort with a large proportion of African Americans." | ( Jain, MK; Kshirsagar, O; Niu, B; Thamer, M; Therapondos, G; Wong, RJ, 2021) |
| "Treatment guidelines for chronic hepatitis B (CHB) do not recommend antiviral therapy for patients in the immune-tolerant phase of the disease, which generally occurs in children who acquire hepatitis B virus (HBV) vertically and may last for decades." | ( Bansal, S; Daniel, JF; Kansu, A; Kelly, D; Martin, C; Mieli-Vergani, G; Tizzard, S; Vergani, D; Wirth, S; Zhou, J, 2021) |
| "Aspirin may reduce the risk of chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) in patients receiving antiviral treatment." | ( Chan, HL; Hui, VW; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC, 2021) |
| "Mothers with chronic hepatitis B were randomised to receive TDF therapy or no treatment during the third trimester." | ( Chen, X; Chen, Y; Dai, E; Duan, Z; Han, G; Jiang, H; Pan, CQ; Wang, Y; Zhang, H; Zhang, S; Zhang, X; Zhao, W; Zhu, B; Zou, H, 2022) |
| "In patients with chronic hepatitis B, the ETV treatment did not result in a higher rate of HCC than the TDF treatment." | ( Choi, H; Seo, GH, 2021) |
| "ETV-treated (≥12 months) chronic hepatitis B patients switched to TAF in routine practice at 15 centers (United States, Korea, Japan, and Taiwan) were included." | ( Arai, T; Atsukawa, M; Cheung, R; Chuma, M; Dang, H; Enomoto, M; Fukunishi, S; Hsu, YC; Ishikawa, T; Jun, DW; Kawada, N; Maeda, M; Nguyen, MH; Nozaki, A; Ogawa, E; Takaguchi, K; Takahashi, H; Toyoda, H; Trinh, HN; Tseng, CH; Watanabe, T; Yasuda, S; Yokohama, K, 2021) |
| "Patients with chronic hepatitis B or C may have a threefold risk of liver dysfunction after receiving antituberculosis treatment." | ( Li, Z; Wu, T; Xin, G; Yu, G, 2021) |
| "He had a history of untreated chronic hepatitis B virus infection for >29 years and no other underlying diseases." | ( Li, Q; Zhu, H, 2021) |
| "Twenty-seven chronic hepatitis B patients treated with entecavir for 10 years were enrolled in this study." | ( An, X; Chen, Y; Li, J; Lin, S; Liu, X; Shi, L; Yang, X; Ye, F; Zhang, X, 2021) |
| "A total of 155 mothers with chronic hepatitis B receiving NAs treatment for preventing mother-to-child transmission during the late gestation period were included and divided into exclusive breastfeeding (n = 63), mixed feeding (n = 34), and artificial feeding (n = 58) groups according to the postpartum feeding methods." | ( Li, EM; Li, JQ; Lin, CS; Mei, YY; Mo, ZS; Xiao, LX; Xu, Z, 2021) |
| "Treatment-naïve chronic hepatitis B patients who had begun ETV or TDF were recruited from four tertiary hospitals." | ( Ahn, SH; Chon, YE; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Lee, HA; Lee, HW; Park, JY; Park, SY; Roh, YH; Seo, YS; Tak, WY, 2022) |
| "However, many chronic hepatitis B patients initiate anti-HBV treatment such as lamivudine and telbivudine with low genetic barriers in China, which leads to compensatory mutations and increases the rate of ETV resistance." | ( Bai, L; Ise, RM; Liu, H; Ran, J; Shang, J; Tang, H; Tu, Y; Zhou, J, 2021) |
| "A total of 58 chronic hepatitis B patients treated with tenofovir disoproxil fumarate (n = 40) and entecavir (n = 18) were included in this prospective study from 2012 to 2016." | ( Çalhan, T; Doğanay, L; Kahraman, R; Kanat, E; Özdil, K; Öztürk, O; Şahin, A; Sayar, S, 2022) |
| "The treatment of chronic hepatitis B (CHB) comprises a global medical problem, and the first-line clinical drugs have obvious shortcomings." | ( Guo, W; Li, M; Liu, Y, 2022) |
| "Tenofovir is wildly used to treat chronic hepatitis B (CHB) infection due to good potency and high genetic barrier to drug resistance." | ( Cen, S; Gu, J; Liu, T; Sun, Q; Zhang, Q, 2022) |
| "Three treatment-naïve cases with chronic hepatitis B (CHB) were reported in terms of a partial response to tenofovir disoproxil (TDF) monotherapy and antiviral-drug resistance." | ( Gedik, H, 2022) |
| "Individuals with chronic hepatitis B virus (HBV) infection who are at substantial risk of HIV acquisition benefit from pre-exposure prophylaxis (PrEP) with tenofovir-based antiviral therapy." | ( Boyd, A; Coffie, PA; Freedberg, KA; Hyle, EP; Kim, AY; Kouamé, MG; Larmarange, J; Mohareb, AM, 2022) |
| "Patients with chronic hepatitis B (CHB) who were administered tenofovir disoproxil fumarate (TDF)-based combination therapy after receiving multiple drugs are frequently switched to TDF monotherapy in South Korea." | ( Choe, WH; Kang, SH; Kim, JH; Kwon, SY; Yoo, BC; Yoon, EL, 2022) |
| "This retrospective study included 289 chronic hepatitis B (CHB) patients without cirrhosis who received entecavir (n = 93), TDF (n = 103), or TAF (n = 86) retreatment for at least 12 months after entecavir or TDF cessation." | ( Chang, KC; Chen, CH; Chiu, SM; Hu, TH; Hung, CH; Lu, SN; Wang, JH, 2023) |
| "Plasmas from chronic hepatitis B (CHB) patients, HBeAg positive or negative, genotype D or E, were fractionated on velocity and equilibrium gradients with or without detergent treatment." | ( Besombes, J; Bomo, J; Genet, V; Gripon, P; Laperche, S; Pronier, C; Thibault, V, 2022) |
| "Plasmas from chronic hepatitis B (CHB) patients, HBeAg positive or negative, genotype D or E, were fractionated on velocity and equilibrium gradients with or without detergent treatment." | ( Besombes, J; Bomo, J; Genet, V; Gripon, P; Laperche, S; Pronier, C; Thibault, V, 2022) |
| "Plasmas from chronic hepatitis B (CHB) patients, HBeAg positive or negative, genotype D or E, were fractionated on velocity and equilibrium gradients with or without detergent treatment." | ( Besombes, J; Bomo, J; Genet, V; Gripon, P; Laperche, S; Pronier, C; Thibault, V, 2022) |
| "For patients with chronic hepatitis B (CHB), the optimal stopping criteria for entecavir or tenofovir disoproxil fumarate treatment remain unclear." | ( Chen, CH; Hu, TH; Hung, CH; Jeng, WJ; Lu, SN; Tseng, TN; Wang, JH, 2023) |
| "For patients with chronic hepatitis B (CHB), the optimal stopping criteria for entecavir or tenofovir disoproxil fumarate treatment remain unclear." | ( Chen, CH; Hu, TH; Hung, CH; Jeng, WJ; Lu, SN; Tseng, TN; Wang, JH, 2023) |
| "A total of 28 patients with chronic hepatitis B, 29 patients treated with thymosin a1 and entecavir combination, and 15 healthy individuals were enrolled in this study." | ( Cao, H; Du, W; Li, F; Wang, K; Yin, S; Zhong, J; Zhong, Q; Zhu, H, 2022) |
| "This study enrolled a total of 160 chronic hepatitis B patients, whose duration of treatment ranged from 12 to 144 months." | ( Guo, Y; Han, J; He, J; Huang, Y; Mao, R; Sun, J; Zhang, J; Zhang, X; Zhang, Y, 2023) |
| "Adult patients with chronic hepatitis B (CHB) on ≥6 months of entecavir/tenofovir treatment between January 2005 and March 2020 were identified using a territory-wide electronic database in Hong Kong." | ( Chan, HL; Hui, VW; Lai, JC; Lai, MS; Liang, LY; Tse, YK; Wong, GL; Wong, VW; Yip, TC, 2023) |
| "In treatment-naïve patients with chronic hepatitis B virus (HBV) infection, entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide have a minimal or no risk of drug-resistance." | ( Choi, J; Choi, WM; Lim, YS, 2023) |